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SUMMARY:
Atherosclerosis, Urokinase-type plasminogen activator and receptor (uPA-uPAR) system, 
Signal transducer and activator of transcription 1 (Stat1), Coculture.
 Atherosclerosis is a major progressive disease of the large arteries causing the dysfunction 
of the heart and the effectiveness of percutaneous vascular therapeutic interventions for 
symptomatic atherosclerotic lesions is limited by vessel restenosis. Although several theories or 
hypotheses about atherogenesis have been proposed during the past decades, none can completely 
explain the whole process of the pathogenesis of atherosclerosis. In spite of this, the concept that 
atherosclerosis is a specific form of chronic inflammatory process resulting from interactions 
between plasma lipoproteins, cellular components (monocyte/macrophages, T lymphocytes, 
endothelial cells and smooth muscle cells) and the extracellular matrix of the arterial wall, is 
now well accepted. After vascular injury, a remodeling process occurs that features leukocyte 
migration and infiltration. Loss of endothelial integrity allows the leukocytes to interact with 
vascular smooth muscle cells (VSMC) and to elicit “marching orders”; however, the signaling 
processes are poorly understood. 
 In the present study mechanism involving inhibition of VSMC proliferation by monocytes 
is elucidated using a direct coculture model. It is shown that monocytes signal the VSMC via the 
urokinase-type plasminogen activator (uPA). The VSMC uPA receptor (uPAR) receives the signal 
and activates the transcription factor Stat1 that in turn mediates the antiproliferative effects. Our 
study for the first time mimics the in vivo events after the loss of endothelial integrity and explains 
the increased VSMC migratory potential and the absence of VSMC proliferation observed at 
the early step of a remodeling process of the vessel wall after vascular injury. Additionally they 
provide an important link between uPA/uPAR-related signaling machinery and human vascular 
disease which may be a useful strategy to drug discovery
 Activation resulting in the nuclear translocation of Stat1 in VSMC upon coculturing with 
activated monocytes was documented by immunofluorescence. The Stat1 nuclear translocation 
is as a result of the interaction of uPA from monocytes and uPAR from VSMC. Blockade of uPA 
and uPAR with specific antibodies led to the inhibition of Stat1 nuclear translocation and further, 
immunofluorescence experiments using cells from uPA and uPAR knock-out mice in the coculture 
system demonstrated the importance of the uPA and uPAR system in the activation of Stat1 and 
involvement of fibrinolytic molecules in the Stat1 induced inhibition of cell growth. The secretion 
of uPA from monocytes and uPAR from VSMC when cocultured were measured by quantitative 
ELISA supported our above hypothesis. 
 The activation of Stat1 involves the phosphorylation of serine and tyrosine residues. With 
the help of immunoblotting it was demonstrated that the phosphorylated Stat1is predominantly 
translocated into the nucleus in VSMC cocultured with monocytes compared to monocultured 
VSMC by using the subcellular fractions and phosphorylation of serine at the position 727 
preponderated the phosphorylation of tyrosine residue at 701. Additionally, activation of Stat1 in 
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VSMC when cocultured with activated monocytes, was shown at the DNA binding level using 
EMSA and supershift assay.
 Upon Stat1 activation, the protein gets dimerized and is translocated to the nucleus, by 
disrupting the microtubules with nocodazole and by immunofluorescence it was shown that the 
cytoskeletal elements are not required for Stat1 nuclear translocation. 
Furthermore IFN-γ plays a pivotal role in host defence mechanism by activating the JAK-
STAT pathway. IFN-γ did not show any additive effect in activating the Stat1 and its nuclear 
translocation which was documented by immunoblot and EMSA.
The antiproliferative effect of Stat1 as a result of uPA induced activation involving 
phosphorylation of Stat1 at ser727 residue and its nuclear translocation is an important event 
involved in this antiproliferative mechanism was shown by blocking the Stat1 at ser727 residue. 
This was accomplished by the microinjection of the antibody against ser727 Stat1 into the VSMC 
and using this microinjected cells in coculture setup with monocytes and further performing single 
cell proliferation assay with these cocultured VSMC. Additionally single cell proliferation assay 
with different combination of cells from uPA and uPAR knock-out mice, VSMC from Stat1 knock-
out mice and Stat1si-VSMC, obtained by RNA silencing for the stable and specific inhibition of 
Stat1 expression in human VSMC using retroviral RNA interference vector in coculture decisively 
supported the above results. 
Finally, immunocytochemical staining for Stat1 and single cell proliferation assay using 
VSMC from uPA knock-out mouse and monocytes derived from wild-type mice in the coculture 
imperatively supported that Stat1 plays an pivotal role in the antiproliferative mechanism and 
ascertained the activation of Stat1 by uPA  via  paracrine loop.  
The above obtained data supported by the earlier findings led the proposal of a novel 
mechanism and throw light on vascular remodeling upon vessel injury. uPA derived from 
monocytes binds to the specific uPAR on VSMC and thereby activates Stat1. This activation 
leads to the dimerization of Stat1 and translocation to the nucleus where it binds to the DNA and 
switches on the expression of a particular gene. This finally results in the inhibition of proliferation 
of VSMC.
Although these identified proteins might already provide new targets in the treatment of 
vascular disorders, the exact signaling mechanisms from cell surface uPAR activation to the Stat1 
activation are still unclear. 
Zusammenfassung
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ZUSAMMENFASSUNG:
Atherosklerose, Urokinase Plasminogenaktivator und Rezeptor(uPA-uPAR) system, Signal 
transducer and activator of transcription 1 (Stat1), Kokultur.
 Die Atherosklerose ist eine bedeutsame, fortschreitende Erkrankung der großen Arterien, 
welche zur Funktionsstörung des Herzens führt. Die Wirksamkeit der perkutanen therapeutischen 
Intervention bei symptomatischen atherosklerotischen Verletzungen der Blutgefäße wird durch die 
Restenosis begrenzt. Obgleich einige Theorien oder Hypothesen der Entstehung der Atherosklerose 
in den letzen Jahrzehnten beschrieben worden sind, ist der gesamte Prozess der Pathogenese der 
Atherosklerose bislang nicht vollständig aufgeklärt. Dennoch ist die Annahme, dass es sich hierbei 
um eine spezifische Form eines chronischen entzündlichen Prozesses handelt, resultierend aus 
Interaktionen zwischen Plasmalipoproteinen, zellulären Komponenten (Monozyten/makrophagen, 
T-Lymphozyten, Endothelzellen und glatten Muskelzellen) und der extrazellulären Matrix der 
Arterienwand, weitestgehend akzeptiert. Nach innerer Verletzung des Blutgefäßes erfolgt ein 
umgestaltender Prozess, welcher die veränderte Migration und Infiltration von Leukozyten mit 
einschließt. Der Verlust der Endothelintegrität ermöglicht Leukozyten mit glatten Muskelzellen 
(VSMC) zu interagieren,wobei die hierbei ablaufenden Signalprozesse jedoch kaum erforscht sind.
 Die vorliegendee Arbeit beschäftigt sich mit der Aufklärung der Mechanismen, die 
zu einer Hemmung der Zellproliferation glatter Muskelzellen durch Monozyten führen. Die 
Untersuchungen wurden in einem direkten Kokultur Modell durchgeführt. Es wurde gezeigt, 
dass Monozyten Urokinase Plasminogenaktivator (uPA) sezernieren und glatte Muskelzellen 
über deren uPA-Rezeptor (uPAR) das Signal empfangen, welches den Transkriptionsfaktor Stat 1 
aktiviert. Die Stat1 Aktivierung wiederum vermittelt die antiproliferativen Effekte in den VSMC. 
Mit Hilfe des Kokultur Modells reflektiert diese Arbeit zum ersten Mal die in vivo Situation 
nach Verlust der Integrität des Endothels und erklärt die verstärkte Migration bei gleichzeitigem 
Fehlen der Proliferation glatter Muskelzellen, wie sie in den frühen Stufen des Umbauprozesses 
der Gefäßwand nach einer Gefäßverletzung beobachtet wird. Zusätzlich wird ein wichtiger 
Hinweis auf eine Verbindung des uPA/uPAR Systems mit Gefäßerkrankungen beim Menschen 
gegeben, welche von Bedeutung für die Entwicklung neuer therapeutischer Ansätze sein kann.
 Die Aktivierung von Stat1in VSMC nach Kokultivierung mit aktivierten Monozyten 
resultiert in der Translokation von Stat1 in den Zellkern und konnte mittels Immunfluoreszenzfärbung 
dokumentiert werden. Die nukleäre Translokation von Stat1 ist das Ergebnis der Wechselwirkung 
von Monozyten sezernierten uPAs und dem uPA-Rezeptor glatter Muskelzellen. Die Blockierung 
von uPA und uPAR mit spezifischen Antikörpern führte zur Hemmung der Translokation von Stat1 in 
den Zellkern. Weiter zeigte die Verwendung kokultivierter uPA- bzw. uPAR defizienter Mauszellen 
in der Immunfluoreszenzfärbung die Bedeutung von uPA und uPAR für die Aktivierung von Stat1 
und die Beteiligung von Komponenten des fibrinolytischen Systems bei der Stat1 induzierten 
Hemmung des Zellwachstums auf. Gestützt wird die obere Arbeitshypthese durch Messungen von 
Monozyten sezernierten uPAs und uPAR von kokultivierten VSMC in einem quantitativen ELISA.
Zusammenfassung
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 Die Aktivierung von Stat1 bezieht die Phosphorylierung der Serin- und Tyrosinreste mit 
ein. Mit Hilfe von Immunoblots zytoplasmatischer und nukleärer Fraktionen wurde gezeigt, 
dass phosphoryliertes Stat1, im Vergleich zu VSMC aus der Monokultur, überwiegend in den 
Zellkern von mit Monozyten kokultivierten VSMC transloziert wurde. Hierbei überwog die 
Phosphorylierung von Serinresten in der Position 727 die Phosphorylierung von Tyrosin701-Resten. 
Weiter wurde die Stat1 Aktivierung in VSMC, welche mit aktivierten Monozyten kokultiviert 
wurden, auf Protein-DNA Bindungsebene mittels EMSA und Supershift Assay gezeigt.
 Nach Aktivierung formt Stat1 Dimere und wandert in den Zellkern. Für die nukleäre 
Translokation von Stat1 werden keine Zytoskelettelemente benötigt, wie durch den Einsatz 
von Nocodazol, das Mikrotubuli zerstört, mittels Immunfluoreszenzfärbung gezeigt wurde. 
 IFN-γ spielt eine zentrale Rolle bei Abwehrmechanismen der Wirtszelle über 
eine Aktivierung des JAK-Stat Signaltransduktionsweges. IFN-γ zeigte unter unseren 
Versuchbedingungen keinen additiven Effekt in Bezug auf die Aktivierung von Stat1 und 
dessen Translokation in den Kern, was mittels Immunoblot und EMSA dokumentiert wurde.
 Die uPA induzierten Aktivierung, sprich die Phosphorylierung von Stat1 am Serin727-
Rest und dessen Translokation in den Zellkern ist von wichtiger Bedeutung für den beobachteten 
antiproliferativen Effekt von Stat1, was durch die Blockierug des Serin727-Restes gezeigt 
werden konnte. Hierzu wurden Antikörper gegen Serin727-Stat1 mittels Mikroinjektion in 
VSMC eingebracht, die darauf folgend nach Kokultivierung mit Monozyten in einem Einzelze
llproliferationsassay untersucht wurden. Die oben genannten Ergebnisse werden bestätigt durch 
Proliferationsassays mit Zellen von uPA- bzw uPAR-defizienten Mäusen, VSMC von Stat1-Ko-
Mäusen sowie Stat1si-VSMC, bei denen durch retroviralen Gentransfer die Stat1 Expression in 
humanen glatten Muskelzellen spezifisch gehemmt wird,. Im weiteren konnten Immunfluoresze
nzfärbungen für Stat1 und Einzelzellproliferationsassays von VSMC aus uPA-Ko-Mäusen und 
Monozyten präpariert aus Wildtyp-Mäusen, die Schlüsselrolle von Stat1 im antiproliferativen 
Mechanismus und die parakrine, uPA induzierte Aktivierung von Stat1 klarstellen.
 Die oben erhaltenen Daten, gestützt durch frühere Untersuchungen, zeigen einen neuen 
Signaltransduktionsweges beim Gefäßumbau nach dessen Verletzung auf. Monozytäres uPA 
aktiviert nach Wechselwirkung mit dem spezifischen Rezeptor (uPAR) glatter Gefäßmuskelzellen 
den Transkriptionsfaktor Stat1. Diese Aktivierung führt zur Bildung von Stat1-Dimeren, 
welche in den Zellkern transloziert werden, dort an spezifische DNA Sequenzen binden 
und die Expression bestimmter Gene anschalten. Letztendlich resultiert eine Hemmung 
der Zellproliferation VSMC aus diesem Zusammenspiel von Monozyten und VSMC.
 Die hier identifizierten Proteine können neue Ansatzpunkte  therapeutischer 
Interventionen sein, wenn auch die genauen Signaltransduktionswege von der Aktivierung des 
uPAR hin zur Aktivierung des Transkriptionsfaktors Stat1 in einzelnen noch ungeklärt sind.
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Figure 1. Diagrammatic representation of the response-to-injury hypothesis of atherosclerosis, delineating the 
different stages of vascular remodeling involving proliferation and migration of VSMC (blue) (Figure from Ross R. 
Nature. 1993 Apr 29;362(6423):801-9. Review)
1 . INTRODUCTION
1.1 Fibrinolytic system in vascular remodeling
 Neointima formation after vessel injury is the most well studied model of vascular 
remodeling, especially accompanied with VSMC migration and proliferation (Figure 1). VSMC 
migration and proliferation are central to the process of restenosis after angioplasty and are also 
involved in the formation of atherosclerotic plaque.
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Upon injury to the vessel wall, there is immediate activation of the coagulation system, 
which is followed by fibrinolysis. Apart from regulating hemostasis, these systems are also 
involved in coordinating the cellular responses to injury that involve processes such as cellular 
adhesion, migration, and proliferation (Esmon, 1995). It has been shown that initial recruitment 
or infiltration of migratory monocytes is one of the most preliminary determining steps that 
commands almost all the stages of vascular remodeling. Endothelial denudation at the site of 
vessel injury leads to infiltration of monocytes which in addition to releasing many biochemical 
molecules directly interact with medial VSMC and trigger them to migrate into the intima and their 
proliferation is associated with extracellular matrix production in the neointima (Schwartz et al., 
1995b). Several cytokines and growth factors released by activated platelets, infiltrating cells, and 
damaged vascular cells are thought to play a role in the process that leads to neointima formation 
in response to vascular injury (Daemen et al., 1991; Lindner and Reidy, 1991; Majesky et al., 
1990). In addition, they express components of the fibrinolytic system, namely the urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR), which are potent chemotactic factors for 
VSMC . However, it remains poorly understood how the various components initiate and sustain 
VSMC migration and proliferation resulting in neointima formation. Recent studies in tissue-type 
plasminogen activator (tPA)–deficient mice (tPA-/- group) and uPA–deficient mice (uPA-/- group) 
demonstrated that these fibrinolytic factors play a critical role in vascular remodeling, particularly 
in the pathogenesis of atherosclerosis and restenosis (Carmeliet et al., 1997d; Carmeliet et al., 
1997b) It has been suggested that the role of tPA is confined to intravascular clot lysis, whereas 
uPA mediates cell migration within the vessel wall (Matsuno et al., 1999). Increased expression 
of the uPAR in atherosclerotic plaques (Noda-Heiny et al., 1995) and knocking-out uPA decreases 
neointima thickening (Carmeliet et al., 1997d) further strengthened the supposed crutial role for 
uPA/uPAR in vascular remodeling.
Fibrinolytic activity is balanced by the levels of plasminogen activators and inhibitors that 
control the formation and action of plasmin. Though primarily mediating fibrin-clot lysis, these 
components are localized to the cell surface through specific receptors (or bound to specific 
extracellular molecules) and hence are also able to regulate pericellular proteolysis-related events 
(Blasi, 1993; Brunner and Preissner, 1994; Bu et al., 1994). The formation of a neointima involves 
remodeling of the extracellular matrix (Carmeliet and Collen, 1996b) as well as activation of latent 
growth factors (Koutsilieris et al., 1993; Odekon et al., 1994) through the plasminogen activation 
system. uPA also induces cellular effects independent of its enzymatic activity, such as stimulation 
of cell chemotaxis(Gyetko et al., 1994), adhesion of monocytes and neutrophils (Sitrin et al., 1996a; 
Waltz et al., 1993), release of tumor necrosis factor-α (Sitrin et al., 1996b), superoxide anion 
production (Cao et al., 1995), and expression of matrix metalloproteinases (Rao et al., 1995), all of 
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which contribute to neointimal formation. Non-proteolytic effects of uPA include also induction of 
intracellular signaling events, such as turnover of inositol phosphate, generation of diacylglycerol, 
phosphorylation of intracellular signaling proteins, and the induction of immediate-early genes 
such as c-fos (Anichini et al., 1994; Bohuslav et al., 1995; Busso et al., 1994; Del Rosso et al., 
1993; Dumler et al., 1993; Dumler et al., 1994; Pacheco et al., 2002; Sitrin et al., 1999). 
1.2 uPA/uPAR system
 uPA is secreted by cells as a single polypeptide chain of 55 kDa (pro-uPA) that can be 
converted to active form by proteolytic cleavage by plasmin and other proteases of other classes 
like cathepsins G and L. Both the single chain and two-chain multidomain uPA, has 3 functionally 
defined independent regions: an amino or N-terminal growth factor domain, a kringle domain 
and a carboxy-terminal domain (Figure 2). The first two domains are collectively reffered to as 
A chain (20 kDa) and C-terminal catalytic serine protease as B chain (34 kDa). The two chains 
are linked by a single disulphide bond. The growth factor domain (GFD) (A chain) contains the 
receptor-binding region of the uPA, corresponding to amino acid residues 20-32 (Apella et al., 
1987). By cleavage with plasmin a low molecular weight uPA can be isolated, which is endowed 
with catalytic activity and inhibitor binding activity but lacking the amino-terminal 135 residues. 
Figure 2. Structure of single chain and double chain multidomain uPA (modified from Tkachuk et al., 1996)
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Pro-uPA, active uPA and amino-terminal 135 residues long fragment of uPA (ATF) bind to cell 
surface uPAR with high affinity (Blasi, 1988), while low molecular uPA does not bind to uPAR.
Upon secretion, the pro-uPA binds to specific cellular receptor (uPAR). The in vivo 
mechanisms by which pro-uPA is converted to active uPA are not completely understood. 
Findings from the last two decades show that binding of pro-uPA with low intrinsic proteolytic 
activity (Petersen et al., 1988) to uPAR does stabilize certain molecular conformation allowing the 
initial activation of plasminogen to plasmin and thus triggering a positive feedback mechanism 
(Manchanda and Schwartz, 1991). Pro-uPA can be activated by certain other proteases. Plasma 
kallikrein, trypsin, thermolysin, factor XIIa, cathepsin G, B and L can cleave the Lys158-Ile159 
peptide bond and NGF-γ can cleave at the plasmin cleavage site thus forming active uPA (Goretzki 
et al., 1992; Ichinose et al., 1986; Kobayashi et al., 1991; Koivunen et al., 1989; Learmonth et al., 
1992; Marcotte and Henkin, 1993). uPA with little plasminogen activating activity (uPA/T) can be 
generated by hydrolyses of the bond at Arg156-Phe157 in pro-uPA by thrombin.
Upon receptor binding uPA is also accessible to and its activity inhibited by PAI-1, PN-1 and 
PAI-2, which belongs to serpin superfamily. When receptor bound uPA is complexed to its above 
said specific inhibitors, it is internalized and degraded (Conese et al., 1994; Cubellis et al., 1990; 
Estreicher et al., 1990; Jensen et al., 1990).
The uPAR is a heavily glycosylated, 55-60 kDa monomeric protein (Nielsen et al., 
1988) encoded as a 313 amino acid residues polypeptide with an additional 22 residues signal 
peptide (Roldan et al., 1990) (Figure 3). It consists of three domains D1, D2 and D3 each with 
approximately 90 residues. It is linked to the cell surface at the carboxy terminus by a glycosylp
hosphatidylinositol (GPI) anchor (Ploug et al., 1991) but lacks a cytosolic and a transmembrane 
domain. The amino terminal domain of uPAR (D1) contains the main uPA-binding-site (Behrendt 
et al., 1991), whereas the other two domain D2 and D3 bind the extracellular matrix vitronectin 
(Wei et al., 1994). In addition to membrane bound form, uPAR is released from the plasma 
membrane by chymotrypsin-cleavage of the GPI anchor and can be found as a soluble molecule 
which is termed as suPAR. In vitro and in vivo, both uPAR and suPAR are proned to cleavage by 
several proteases including physiologically relevant enzymes such as neutrophil elastase, plasmin 
and uPA itself in the region that links domain D1 to domain D2 (amino acids 82-95) to yield a D1 
fragment and a D2D3 fragment (Ploug et al., 1994). The D2D3 fragment has direct chemotactic 
activity (Ploug et al., 1994).
In many pathophysiological conditions such as tumor invasion, angiogenesis, and 
inflammation, cell migration and invasion are considered to be important steps. These are 
controlled by the uPA/uPAR system by regulating extracellular proteolysis, cell adhesion and 
signal transduction. 
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It has been indicated by several datas that the biological properties of uPAR, can be 
modified by a conformational changes in uPAR. For example, the uPA binding to uPAR causes the 
appearance of novel binding sites for vitronectin (Higazi et al., 1996b; Hoyer-Hansen et al., 1997b; 
Sidenius and Blasi, 2000b; Waltz and Chapman, 1994), thrombospondin (Higazi et al., 1996b), 
uPAR associated protein (Behrendt et al., 2000) and the disappearance of binding site for α
2
-
macroglobulin receptor (Higazi et al., 1996b). Further, uPA induced chemotaxis can be mimicked 
by the proteolytic cleavage of uPAR generates uPAR fragments that act as potent inducers of 
chemotaxis in cells lacking endogenous uPAR (Fazioli et al., 1997; Resnati et al., 1996). Although 
there are extensive evidence that uPAR is involved in complex interactions with other proteins, 
very little is known about how these interactions are regulated at the molecular level. In this line 
of research it has been shown that the ability of uPAR binding to vitronectin which induces cell 
adhesion (Higazi et al., 1996b; Hoyer-Hansen et al., 1997b; Sidenius and Blasi, 2000b; Waltz and 
Chapman, 1994) and to change gene expression during the differentiation of human myeloid U937 
cells (Rao et al., 1995).
1.3 Jak-Stat signaling pathway
Cells of the immune system communicate with each other to initiate, establish and mediate 
immune responses. The vascular system, particularly arteries comprise predominantly with smooth 
muscle cells. The communication of the cells of the immune system with the VSMC occurs 
through cell-to-cell contact or through a variety of intercellular mediators that include cytokines, 
chemokines, growth factors, hormones and regulatory proteases which acts as regulators of 
Figure 3. Structure of uPAR showing the three different domains with the five potential N-Glycosylation sites (modified 
from Ploug et al.,1994)
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Figure 4. A flow diagram representing the Jak-Stat pathway: Stimulation with growth factors or cytokines at the 
cell surface results in receptor activation  and subsequent phosphorylation of Stats via phosphorylation of Jaks. 
Phosphorylation of Stats induces dimerization and translocation to the nucleus, where Stat dimmers bind to specific 
Stat response elements and directly regulate gene expression. The suppressor of cytokine signaling (SOCS) family 
of proteins dampen receptor signaling via homologous or heterologous feedback regulation (modified from Sigma-
Aldrich on-line catalogue).
important functions. Many of these above said molecules are of biological importance and play 
central roles in the regulation of a wide array of cellular functions in the lympho-hematopoietic 
system. These factors stimulate proliferation, differentiation and survival signals in addition to 
specialized role in host resistance to pathogens. These molecules elicit their effects by activating 
multiple signaling pathways that together mediate these important cellular functions. The Jak-Stat 
pathway has been recently elucidated as a remarkably simple pathway which transmits information 
received from extracellular signals, through receptors having transmembrane domains, directly 
to target gene promotors in the nucleus providing a mechanism for transcriptional regulation 
without the aid of a second messengers (Figure 4). Although this pathway was found initially 
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to be activated by interferons, it is now known that a large number of cytokines, growth factors, 
hormonal factors and even some regulatory proteases like uPA activate Jak and/or Stat proteins. 
Further more, recent findings have suggested that the interdependence of Jaks and Stats might not 
be absolute as originally thought.
1.3.1 The JAK family of protein tyrosine kinases
In the early 1990s the search for the protein kinases led to the discovery of a novel family 
of intracellular non-receptor tyrosine kinases, the Janus Kinases or Jaks. At present there are four 
identified mammalian Janus kinase (Jak) family members : Jak1, Jak2, Jak3 and Tyk2 are highly 
related proteins of 120-140 kDa. Initially identification of Jak1, Jak2, and Tyk2 through different 
cDNA-cloning approaches as kinases whose ubiquitous expression gave no hint to their function 
derived them the names Janus (the Roman God with two heads) or Jak (just another kinase) 
(Ziemiecki et al., 1994). The fourth mammalian member Jak3 was cloned on the basis of similarity 
and was found to be predominantly expressed in hematopoietic cells, though low expression was 
reported recently in normal and transformed human cell types of various origins (Ihle, 1995; Lai 
et al., 1995; Verbsky et al., 1996). A Drosophila homologue, Hop, was found associated with 
the Hopscotch mutations (Binari and Perrimon, 1994). Jaks are also known in Xenopus laevis, 
Caenorhabditis elagans and fish. Amino acid sequence alignment of the Jaks revealed that they 
possess seven highly conserved domains (JH1-JH7; figure 5). In the recent years pioneering works 
on interferon signaling and the functional complementation of three mutant cell lines with genomic 
DNA or cDNAs encoding the Jaks, the role of these enzymes as esential effectors in interferon 
(IFN) α/β and IFNγ signaling was firmly established (Darnell et al., 1994). 
Figure 5. Structure of Jaks
Jaks are structurally unique in having tandem kinase and kinase-like domains. The C-terminal kinase domain is the 
catalytic domain, and the precise function of the kinase-like domain has yet to be determined. Regions of homology 
shared by Jaks have been termed Jak homology (JH) domains. They are named in a C-terminal-to-N-terminal direction. 
The JH1 and JH2  domain is the kinase domain and the The remainder of the homology domains are indicated though 
their functions are not well understood. The N-terminus of the Jaks, however, appears to be important for association 
with cytokine receptor subunits (modified from Leonard and O´shea, 1998)
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Compelling evidence was obtained that dozens of soluble mediators or cytokines, ranging 
from growth and/or differentiation factors to hormonal polypeptides, pleiotropic interleukins and 
regulatory proteases like uPA utilised Jaks as immediate intracellular effectors (Briscoe et al., 
1994; Ihle, 1995; Taniguchi, 1995). For example in the case of intercellular signaling molecule 
cytokine, which share a common α-helical structure and utilize a group of structurally related 
receptors (Nicola, 1994). The cytokine receptor superfamily comprises polypeptides with a 
single transmembrane domain and common extracellular structural motifs that are important for 
ligand binding (Bazan, 1990; Thoreau et al., 1991). Since these molecules do not posses intrinsic 
catalytic activity, they rely on Jaks, which are constitutively associated with their cytoplasmic 
regions, to transduce the extracellular ligand-binding event to an intracellular signal. Motifs 
called box 1, usually proline rich and box 2 in the membrane proximal regions of the receptors 
are important for Jak association. The fundamental role of Jaks in cytokine signaling is evidenced 
by the inherited immunodeficiencies caused by mutations that block receptor-Jak interactions or 
the kinase activity of the Jaks. Activation of Jaks occurs within minutes of ligand binding and as 
a result the kinases are brought together as a result of dimerization/oligomerization or, as ligand-
induced conformational changes of pre-existing dimers (Livnah et al., 1999; Remy et al., 1999). 
In the case of homodimeric receptors, e.g., for growth hormone (GH), prolactin, thrombopoietin 
(TPO) and erythropoietin (EPO), only Jak2 is activated. In contrast, heteromeric receptors, made 
up of different subunits, activate distinct combinations of Jaks. Upon activation Jaks proceed to 
phosphorylate the receptor subunit(s) as well as other substrates. Stat proteins are one of the most 
intensely studied substrates of Jaks, which will be discussed later in detail and in particular Stat1 
is the candidate of this study.
In addition to have a pivotal role in cytokine signaling, Jaks also have accessory roles in 
other pathways. It has been reported that Jaks get phosphorylated and activated after stimulation 
with growth factors whose receptors are known to posses intrinsic ligand-inducible tyrosine kinase 
activity like colony stimulating factor (CSF)-1 (Novak et al., 1996), epidermal growth factor (EGF) 
(Leaman et al., 1996b), platelet-derived growth factor (PDGF) (Vignais et al., 1996), Insulin and 
Insulin like growth factor (IGF)-1 (Gaul et al., 1998). Jaks also appear to be involved in signaling 
by G-protein-coupled receptors, including those for angiotensin (Marrero et al., 1995), serotonin 
(Guillet-Deniau et al., 1997) and α-melanocyte-stimulating hormone (Buggy, 1998). Recently, it 
has been reported that Jak2 interacts directly with the cytoplasmic tail of the angiotensin receptor 
(Ali et al., 1997). Jaks, particularly Tyk2 in association with Stat3 is activated by the peptide 
hormone bradykinin (BK) signaling (Hong et al., 2000). The Jaks along with Stats can also be 
activated in response to tumor necrosis factor (TNF) (Guo et al., 1998), osmotic shock (Gatsios 
et al., 1998) and upon ligation of MHC-I (Skov et al., 1998b) and CD40 proteins (Hanissian and 
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Geha, 1997). In addition, the Jak-Stat signaling pathways are regulated by a vast array of intrinsic 
and environmental stimuli, which can add plasticity to the response of a cell or tissue.
Jaks are only part of whole story in the signaling cascade. Upon activation of Jaks, 
many cytoplasmic proteins get involved and interact and finally signaling cascade effect in 
gene expression. The knowledge of revelant Jak substrates is quite limited. Aside from kinases 
themselves being substrates, which is a paradigm, cytokine receptors is another class. Tyrosine 
phosphorylation of receptors forms docking sites for proteins with phosphotyrosine binding 
domain, which in turn are also Jak substrates. The Stat (Signal Transducers and Activators of 
Transcription) family of transcription factors is one such example and the adaptor molecule Shc 
is another. Grb2, SHP-2, Vav and STAM are other proteins that interact with Jaks (Chauhan et al., 
1995; Matsuguchi et al., 1995; Takeshita et al., 1997; Yin et al., 1997). In this direction discovery 
of Stats provides important insights as to how extracellular signals effect gene expression.
1.3.2 Stats (Signal transducers and activators of transcription)
Stats are latent cytosolic transcription factors utilized in signaling triggered by cytokines, 
chemokines, growth factors, hormones and regulatory proteases which act as regulators of important 
functions. The seven Stat proteins identified in mammals are denoted as Stat1, Stat2, Stat3, 
Stat4, Stat5a, Stat5b and Stat6. They range in size from 750-850 amino acids. The chromosomal 
distribution as well as identification of Stats in more primitive eukaryotes, suggests that this 
family originated from a single primordial gene. As eukaryotes emerged more and more complex, 
duplication of this locus appear to reflect an increasing need for cell-to-cell communication. 
Consistent with this evolutionary pattern, Stats share structurally and functionally conserved 
domains. This includes the amino-terminal domain (NH2), the coiled-coiled domain (CCD), 
the DNA binding domain (DBD), the linker domain and the SH2/tyrosine activation domain. In 
contrast to other domains, the carboxy-terminal transcriptional activation domain (TAD) is quite 
divergent and contributes to Stat specificity. Though there is limited number of Stats, as they have 
achieved significant specificity it is possible for over 50 members of hematopoietin family to 
transduce signals. This is largely because the receptors that transduce signals for these cytokines 
can be placed into five structurally and functionally related subfamilies, each of which tend to 
transduce signals through a single Stat protein (refer to the Table 1). 
Additionally, tissue specificty and activation of other signaling pathways by these receptors 
contribute to the specificity. The following section highlights the structural, functional and 
regulatory properties of the mammalian Stat family.
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CYTOKINE / GROWTH FACTOR JAK KINASE ACTIVATED STATS ACTIVATED
Type I cytokines
Cytokines whose receptors share γ
c
IL-2, IL-7, IL-9, IL-15 Jak1, Jak3 Stat5a, Stat5b, Stat3
IL-4 Jak1, Jak3 Stat6, Stat5a, Stat5b
IL-13 Jak1, Jak2, Tyk2 Stat3, Stat6
IL-21 Jak1, Jak3 Stat1, Stat3, Stat5
TSLP none Stat5
Cytokines whose receptors share β
c
IL-3, IL-5, GM-CSF Jak2 Stat5a, Stat5b
Cytokines whose receptors share gp 130
IL-6, IL-11, OSM, CNTF, CT-1 Jak1, Jak2 Stat1, Stat3
IL-12 Tyk2, Jak2 Stat4
Leptin Jak2 Stat3
IL-23 ? Stat4
NNT-1/BSF-3 Jak1, Jak2 Stat1, Stat3
G-CSF Jak1, Jak2 Stat3
Cytokines with homodimeric receptors
GH Jak2 Stat5a, Stat5b, Stat3
PRL Jak2 Stat5a, Stat5b
EPO, TPO Jak2 Stat5a, Stat5b
Type II Cytokines
IFNγ Jak1, Jak2 Stat1, Stat2
IFN-αs/β/ω/Limitin Jak1, Tyk2 Stat1, Stat2, Stats3-6
IL-10 Jak1, Tyk2 Stat3
IL-19, IL-20, IL-24 ? Stat1, Stat3
IL-22 Jak1, Tyk2 Stat1, Stat3, Stat5
Growth factors
EGF Jak1, Jak2 Stat1, Stat3, Stat5
PDGF Jak1, Jak2 Stat1, Stat3, Stat5, Stat6
VEGF ? Stat1, Stat3, Stat5, Stat6
HGF ? Stat1, Stat3
CSF-1 Jak1, Tyk2 Stat1, Stat3, Stat5
Seven transmembrane domain receptors
Angiotensin II AT1 Jak2, Tyk2 Stat1, Stat2
Table 1. Activatuion of Jaks and Stats. In certain receptors , the Jaks and Stats with essential signaling functions 
discovered to date are indicated in bold (modified from Leonard and O´shea, 1998; Kisseleva et al., 2002; Schindler, 
2002)
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1.3.2.1 Structure of Stat proteins
As mentioned above the six conserved domains are identified by structural and functional 
analysis. The crystal structure of two Stats, Stat1 and Stat3, bound by DNA has been solved, but 
the structures did not include the amino and carboxy-terminal portions of the molecules reviewed 
in (Horvath, 2000). Figure 6 shows the crystal structure of Stat1 DNA complex and domains of 
Stat in general and Stat1 in particular.
1.3.2.2 N-terminal domain
The N-terminal domain, comprising approximately 130 amino acids, is conserved among the 
Stats (51% sequence identity between Stat1 and Stat4; 20% between Stat5 and Stat6). It represents 
an independently folded and stable moiety, which can be cleaved from the full-length molecule by 
limited proteolysis (Vinkemeier et al., 1996). The crystal structure of Stat4 (amino acids 1-124) 
reveals a dimer (Vinkemeier et al., 1998). The interface of this dimer is formed by a ring-shaped 
element consisting of five short helices. Several studies suggests that this N-terminal dimerization 
stabilizes binding of the dimers to tandem GAS elements (Vinkemeier et al., 1996; Vinkemeier et 
al., 1998; Xu et al., 1996). Further, studies have shown that the N-terminal Stat domain promotes 
interaction with transcriptional coactivator CBP/p300 (Horvath, 2000), the PIAS family (Shuai, 
2000), receptor domains (Leung et al., 1996) and that it regulates nuclear translocation (Strehlow 
and Schindler, 1998).
1.3.2.3 Coiled-coil domain
The coiled-coil domain consists of four α-helices comprising approximately 135-315 amino 
acids. It is linked to the N-terminal domain by a flexible polypeptide chain (24 amino acids for 
Stat1 and 18 amino acids for Stat3). The crystal structure of Stat1 and Stat3 reveals that this 
domain protrudes about 80 Å laterally from the core structure (Becker et al., 1998; Chen et al., 
1998). This domain is predominant hydrophilic surface, which takes part in specific interactions 
with other helical proteins. The interacting proteins include p48/IRF9, the transcription factor c-
Jun, N-myc interacting protein (Nmi) and StIP (Collum et al., 2000; Horvath et al., 1996; Zhang 
et al., 1999b; Zhu et al., 1999). Recent studies have implicated the coiled-coil domain in receptor 
binding, tyrosine phosphorylation and nuclear export (Begitt et al., 2000; Zhang et al., 2000b).
1.3.2.4 DNA-binding domain
The DNA binding domain, which occupies approximately between 320-480 amino acid 
residues is a β-barrel with an immunoglobulin fold and lies carboxy-terminal to the coiled-coil 
domain. This structure is reminiscent of NF-κB and p53 DNA binding domains (Chen et al., 1998). 
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Figure 6. Structure of Stats
Schematic  diagram showing the domains of Stat in general and Stat1 in particular and additionally the crystal 
structure of the Stat1 DNA complex (modified from Leonard and O´shea, 1998 and Chen et al., 1998 ). 
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The cooperativity in DNA binding is likely to be important in effective transcriptional activity, 
which is supported by the finding that the number of contact sites between amino acid residues 
and DNA are moderate. Also the dissociation constant is in nanomolar range. As the DNA binding 
domain shows different conformation (prior to activation) in the inactive state it is appearing to 
consider that it may have other additional functions (McBride et al., 2000).
1.3.2.5 Linker domain
The linker domain connects the DNA-binding domain with the SH2/dimerization domain. 
Studies suggest that the linker domain interacts both with the SH2 domain and DNA binding domain 
(Chen et al., 1998) and in turn mutational studies have also implicated that the transcriptional 
regulation by the linker domain in Stat1 (Yang et al., 1999).
1.3.2.6 SH2 domain and tyrosine activation motif
SH2 domain plays an important role in signaling as they are capable of binding to specific 
phosphorylated tyrosines. Stat proteins have conserved SH2 domain (approximately residues 
between 580-680) though they are divergent from other SH2 domains. It consists of an anti-
parallel β-sheet flanked by two α-helices, which form a pocket. At the base of this pocket lies a 
highly conserved arginine (Arg-602 for Stat1, Arg-609 for Stat3), which mediates the interaction 
with phosphate. The ability of this SH2 domain to recognize specific phosphotyrosine motifs plays 
an essential role in three Stat signaling events: (1) recruitment to the cytokine receptor through 
recognition of specific receptor phosphotyrosine motifs, (2) association with the activating JAK 
(Barahmand-Pour et al., 1998; Gupta et al., 1996) and (3) STAT homo- or heterodimerization (Gupta 
et al., 1996; Shuai et al., 1994). Interaction between the SH2 domain of one Stat monomer and the 
tyrosine phosphorylated tail segment of the other monomer results in Stat dimerization. Residues 
most involved in defining the specificity of the interaction between the SH2 domain and tyrosine 
motif are located at positions +1, +3 and +5, +6, +7 C-terminal to the phosphotyrosine (Chen et 
al., 1998). Closely positioned amino acids of the SH2 domain (e.g. Ala-641, Val-642) appear to 
participate in this interaction. All Stats except Stat2 have been shown to form stable homodimers 
in vitro and in vivo. Additionally, many STATs, including Stat2, can heterodimerize with other 
Stats through this reciprocal SH2-phosphotyrosine interaction (Darnell Jr, 1997; Schindler and 
Darnell, 1995). As each STAT has both an SH2 domain and a phosphorylated tyrosine these 
dimers are stabilized by bivalent interactions. The bivalent nature of these interactions helps to 
explain why dimerization of Stats is favored over the monovalent interaction of the Stat SH2 with 
a phosphorylated receptor.
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1.3.2.7 Transcriptional activation domain (TAD)
Consistent with its ability to regulate unique transcriptional responses, the carboxy-terminal 
domain is poorly conserved among the Stats. The first evidence that the carboxy-terminus encodes 
transcriptional activation domain (TAD) came from a comparative analysis of the full-length 
Stat1 and an alternatively spliced isoform Stat1β, which lacks the last 38 carboxy-terminal amino 
acids (Schindler et al., 1992). Well characterized C-terminally truncated isoforms have also been 
identified for Stat3, Stat4 and Stat5 (Schindler and Strehlow, 2000). They appear to function 
as dominant-negative regulators. Although a detailed understanding of how the Stat carboxy-
terminus regulates transcription remains to be determined, important progress has been made. For 
example, it has been determined that the transcriptional activity of several Stats can be modulated 
through serine phosphorylation within the TAD, reviewed in (Decker and Kovarik, 2000). Serine 
phosphorylation appears to enhance the transcription of some, but not all target genes.  It has 
been suggested that TAD phosphorylation could allow for regulation and crosstalk by different 
receptors which may involve the recruitment of other transcription factors and coactivators. Serine 
phosphorylation may alter the affinity for other transcriptional regulators like MCM5, BRCA1, 
CBP/p300 and c-Jun (Horvath, 2000).
1.4 STAT activation
Structural studies of several hematopoietin receptors from the cytokine family indicate that 
ligand binding promotes the dimerization of receptors into an active conformation (Wells and 
de Vos, 1996). In each case activation is believed to lead to close approximation of cytoplasmic 
receptor tails, enabling the transphosphorylation (i.e. activation) of the receptor-associated Jaks. 
Activated Jaks then phosphorylate specific tyrosine motifs present in the receptor endodomains, 
which in turn mediate the recruitment of Stats to their appropriate receptor. This entails the ability 
of Stat SH2 domains to recognize a phosphotyrosine residue and 4–5 carboxy-proximal amino 
acids, known as the receptor Stat recruitment motif. Table-1 summarizes functional groups into 
which hematopoietin receptors can be divided and Jak and Stat family members they activate.
1.5 Nucleocytoplasmic transport of Stats
Stats which are predominantly localized in the cytoplasm, upon activation (phosphorylation 
and dimerization) rapidly translocate to the nucleus and induce gene expression. After termination 
of the signal, Stats translocate back to the cytoplasm. This regulated mobilization of Stats is an 
essential step for signaling and is mediated by the nuclear pore complex (NPC) (Doye and Hurt, 
1997). Stats are transported across the NPC in an active bidirectional process that is energy and 
activation dependent.
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Although dimerization presumably unmasks a short amino acid sequence (residues 
i.e.arginines and lysines) called a nuclear localization signal (NLS), which directs active nuclear 
import of protein. The residues comprising the Stat NLS are not well defined. The rapid and 
ligand-dependent nuclear import of Stats was an important feature recognized during the initial 
characterization of Stat1 and Stat2. Moreover, this was found to be dependent on tyrosine 
phosphorylation and independent of an association with the cytoskeleton (Lillemeier et al., 2001). 
Several groups have attempted to locate the elusive Stat NLS through mutagenesis of arginine/
lysine-rich motifs. Recently, the identification of putative NLS elements in cytokine receptors 
and ligands led to the speculation that Stats may translocate to the nucleus through association 
with other signaling components (Sekimoto et al., 1997; Subramaniam et al., 2000). It has been 
reported that Stat1 translocates to the nucleus by a gain-of-function mechanism, it is not anchored 
in the cytoplasm and does not constitutively shuttle in and out of the nucleus (McBride et al., 
2000). Following specific tyrosine phosphorylation, Stat1 dimerizes via intermolecular SH2–
phosphotyrosine interactions and this dimerization appears to trigger a conformational change 
in the Stat1 molecule that reveals a functional NLS. A number of reports together indicate that 
dimerization is required to facilitate the functional appearance of an NLS on STATs (Bromberg 
and Darnell, 1999; McBride et al., 2002; Milocco et al., 1999). 
 Classical NLSs bind to central armadillo repeats in the importin- receptors; however, 
tyrosine-phosphorylated Stat1 binds to a C-terminal domain that does not overlap with the central 
armadillo repeats (Conti et al., 1998; Fontes et al., 2000; Sekimoto et al., 1997). STAT1 is the only 
known imported substrate that interacts with the C-terminus of importin. This finding supports the 
hypothesis that the Stat1 NLS does not conform to a classical NLS. The DNA binding domain of 
Stat1 appears to have evolved with NLS and NES motifs that may overlap and serve to direct the 
Stat1 protein to its proper cellular localization. The position of the NLS and the NES within the 
DNA binding domain of Stat1 suggests an elegant mechanism to regulate cellular localization of a 
signal transducer and activator of transcription.
Analogous to import, nuclear export is specified by nuclear export signals (NES), which 
are characterized by a leucine rich amino acid sequence (Fornerod et al., 1997). In contrast to 
the poorly understood mechanism of Stat nuclear import, recent studies have provided important 
insights into how this protein is exported from the nucleus during the period of signal decay that 
follows stimulation. In summary, more recent progress has been made in understanding how Stats 
are exported from the nucleus, then imported. Unexpectedly, these studies indicate that in resting 
cells Stats are continuously exported from the nucleus, raising some intriguing new questions 
about Stat regulation.
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1.6 Stat DNA binding
Once in the nucleus, in general, the Stat homodimers or heterodimers can directly bind 
to DNA. However, investigation of IFN responses has identified two different transcriptional 
enhancers within the promoter elements of STAT target genes (Decker et al., 1997b; Kessler 
et al., 1988; Schindler and Brutsaert, 1999b). Type I IFNs (α, β, ω Limitin) signal through the 
formation of ISGF-3 complexes, which bind to ISRE sites (IFN stimulated response elements) and 
initiate gene transcription (Kessler et al., 1988). Comparative analysis of IFN-α response elements 
revealed an ISRE consensus consisting of two tandem sequences, AGTTTN
3
TTTCC. Among the 
proteins that compose the ISGF-3 complex, IRF-9/p48 plays a critical role in recognizing the ISRE 
site. Stat1 also promotes contact with the additional flanking nucleotides, whereas Stat2 does not 
directly interact with the DNA (Qureshi et al., 1995).
IFN type II signals (γ) through Stat1 homodimers, which bind to a distinct response 
element, the GAS (Decker et al., 1997b). This palindromic element has a consensus sequence of 
TTTCCNGGAAA. Similar responsive elements have been identified in the promoters of other 
Stat-induced genes. Biochemical studies have determined that TTCN
2–4
GAA consensus defines 
the optimal binding site for all Stats, with an exception for Stat2, which appears to be defective 
in DNA binding. This provides an opportunity for most Stat homodimers to exhibit unique DNA 
binding preferences. In part this is determined by spacing between palindromic half sites. Thus, 
Stat1 binds to an element with a canonical n=3 spacing, while Stat3 and Stat6 favor elements 
where n=2 and n=4, respectively (Decker et al., 1997b; Ehret et al., 2001). Additionally, recent 
studies indicate that the ability of Stats to bind cooperatively to tandem GAS elements (6–10 bp 
apart) also contributes to DNA binding specificity. Moreover, these tandem sites often include 
nonconsensus GAS elements (Ehret et al., 2001; Soldaini et al., 2000).
1.7 Regulation of the Jak-Stat signaling pathway
The Jak-Stat pathway is important for many host responses including defense, differentiation, 
proliferation, and oncogenesis. It is, therefore, not surprising that numerous regulatory layers exist 
to modulate this signaling pathway. This includes both negative and positive regulation. The effect 
of these regulatory processes determines the rate at which Stat signals are transduced.
1.8 Negative regulation of Stat signaling
Cells have innate mechanisms to protect themselves from repeated stimulations from 
external stimuli under certain physiological conditions by down regulating the signals in the 
signaling cascade. In the case of pathway involving Stat proteins, there are several switch-off 
points in the signaling cascade at the levels of receptors, Jaks and the Stat molecules themselves. 
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There are studies reporting receptor endocytosis (Dittrich et al., 1996). Stat proteins and also the 
receptors have been found to be targets of Ubiquitin-proteosome mediated degradation (Haspel 
et al., 1996; Kim and Maniatis, 1996). As it is mentioned earlier, Jak activation is dependent 
on tyrosine phosphorylation so it has been found that the phosphatases containing SH2 domain 
negatively regulates Jak activity (Jaio et al., 1997; Yi et al., 1993) and in turn Stat dependent 
signaling. The CIS/SOCS/JAB/SSSI family of proteins have the ability to serve in a more classical 
ʻfeedback loop  ʼto down regulate the Stat dependent signaling (Krebs and Hilton, 2003; Nicholson 
and Hilton, 1998; Starr and Hilton, 1998). 
The mechanism by which it acts in down regulating remains to be fully elucidated. Yeast two 
hybrid screens have identified a number of Stat interacting proteins including the PIAS (Protein 
Inhibitor of Activated Stats) family, reviewed in (Shuai, 2000). PIAS appears to bind to activated 
Stat dimers, thereby blocking their ability to bind DNA (Liao et al., 2000). Further intensive studies 
should help to define the overall significance of PIAS proteins in the regulation of Stat signaling.
1.9 Positive regulation of Stat function
Although initial studies focused on the role tyrosine kinases play in Stat activation, more 
recent studies have identified other positive regulators. This includes serine kinases and interacting 
proteins. 
1.9.1 Serine phosphorylation
The recognition that Stats can be modified by serine phosphorylation raised the possibility 
of cross-talk between signaling cascades (Decker and Kovarik, 2000). Initial studies demonstrated 
phosphorylation of serine 727, in a PMSP motif, in both Stat1 and Stat3 (Wen et al., 1995; Zhang 
et al., 1995). Although there is little sequence homology between the TADs, several TADs have 
conserved a serine residue at or near position 727 that is phosphorylated in response to ligands 
and are prerequisites for maximal transcription activity (Wen et al., 1995; Zhang et al., 1998b). 
The conservation of the PMSP motif in the carboxy-termini of Stat1, Stat3, Stat4, and Stat5, raised 
the possibility that proline-directed serine kinases (e.g. MAP kinases (Gonzalez et al., 1991)) 
were responsible for this modification. This issue remains controversial, however, in part because 
different serine kinases have been found to phosphorylate Stat1 and Stat3 depending on the nature 
of the stimulus and co-stimulus (Decker and Kovarik, 2000). Recent studies have shown that 
CaMKII as the downstream serine kinase that phosphorylates S727 in Stat1 critical for IFN-γ-
induced gene activation (Jayashree et al., 2002). Reporter gene studies have determined that serine 
phosphorylation enhances transcriptional activity of Stat1 and Stat3 (Decker and Kovarik, 2000; 
Wen et al., 1995). More physiological studies in Stat1 deficient cells reconstituted with Stat1 and 
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Stat1S727A demonstrated that serine phosphorylation only enhances the ability of Stat1 to drive 
expression of some, but not all target genes (Kovarik et al., 2001). Recent studies also indicate that 
serine phosphorylation enhances Stat4 transcriptional activity (Visconti et al., 2000). Although 
both Stat5 and Stat6 can become serine phosphorylated, enhanced transcriptional activity has not 
convincingly been demonstrated (Yamashita et al., 1998). Rather, for Stat5, serine phosphorylation 
appears to enhance protein stability (Beuvink et al., 2000). 
1.10 Interaction with other transcription factors and cellular proteins
The transcriptional regulation of eukaryotic genes involves the specific and ordered 
interaction of a large number of proteins including enhancer/promoter specific transcription 
factors, chromosomal remodeling complexes and components of the basal transcriptional 
machinery (Maniatis et al., 1998; Pugh, 2000). Consistent with these observations, numerous 
studies have described a robust interaction between Stats and other transcriptional regulators. 
The first evidence of an interaction between Stats and other transcription factor was evident when 
IRF-9 (p48) co-purified with Stat1 and Stat2 in the ISGF-3 complex (Schindler and Strehlow, 
2000). Subsequent analysis of Stat dependent promoters provided both functional and biochemical 
evidence for the interaction with other transcription factors. Stat1 was shown to interact with NF-
κB, Sp1, USF-1, PU.1 and the glucocorticoid receptor (Aittomaki et al., 2000; Look et al., 1995; 
Muhlethaler-Mottet et al., 1998; Ohmori et al., 1997). Stat3 was shown to interact with Sp1, c-Jun 
and the glucocorticoid receptor (Cantwell et al., 1998; Schaefer et al., 1997; Zhang et al., 1999b). 
Stat5 was shown to interact with YY-1, Sp1, C/EBPβ and the glucocorticoid receptor (Martino et 
al., 2001; Meier and Groner, 1994; Stocklin et al., 1996; Wyszomierski and Rosen, 2001). Stat6 
has been shown to associate with NF-κB and C/EBPβ (Mikita et al., 1998; Shen, 1998). 
Other studies have demonstrated the association between Stats and proteins that facilitate 
transcription through chromatin modification. Yeast two hybrid screens have played an important 
role in these studies. Not unexpectedly, the first chromosome modifying proteins shown to interact 
with a Stat (i.e. Stat2) were CBP/p300 (Bhattacharya et al., 1996). Subsequent studies have 
demonstrated functional and physical association between CBP/p300 and other STATs (Horvath, 
2000). More recently other chromatin modifying proteins have been shown to associate or function 
with Stats. They include BRAC1, Mcm5, Nmi and HMG-I(Y) (Kim et al., 2001; Ouchi et al., 
2000; Zhang et al., 1998b; Zhu et al., 1999). Finally, yeast two hybrid screens have identified non-
nuclear proteins that associate with Stats. This includes: StIP1, a novel cytosolic WD40 protein 
that appears to facilitate the interaction between Jaks and Stats; STAM, a Jak binding protein; and 
SH2-B, a GH receptor binding protein (Carter-Su et al., 2000; Collum et al., 2000; Takeshita et 
al., 1997). 
Introduction
24
Detailed analysis of several eukaryotic promoters suggests that the modest number of 
interactions outlined in this field may grow to a substantial number as Stat dependent promoters 
begin to undergo more rigorous scrutiny e.g. (Kim et al., 2001; Zhang et al., 1999b). These studies 
are also likely to provide insight into the ability of Stat modifications, like serine phosphorylation, 
to differentially regulate the expression of some genes.
1.11 Biological importance of Stat1
In addition to Stat1being activated by IFNγ, it has been reported recently that it might be 
activated by many growth factors including IL-6, IL-10, growth hormons, lipopolysaccharides, 
UV and thrombopoietin.
Exclusively Stat1 and Stat2 are considered important in mediating IFN stimulatory effects. 
Animal that lack Stat1 or Stat2 are extremely sensitive to microbial infections (Durbin et al., 
1996; Meraz et al., 1996; Park et al., 2000). Stat1 is reported to be an important candidate for IFN-
dependent signaling pathways, as Stat1 deficient mice is defective in responding in IFN dependent 
immune responses against viral and microbial pathogen infection (Durbin et al., 1996; Meraz et 
al., 1996). Studies with Stat1 defecient mice shows that it is primarly important for IFN- dependent 
signaling. These mice show impairment in responding to IFN dependent immune responses against 
viral and microbial pathogen infections. But these mice respond to other cytokines and do not have 
any other developmental abnormalities. Stat1 is known to be a strong antiproliferative agent and 
plays a pivotal role in ligand mediated growth arrest and apoptosis. Stat1 defecient fibroblasts do 
not arrest growth in response to IFNα or γ and osteosarcoma-derived cells defecient in Stat1 do 
not apoptose in response to IFNγ or TNF (Migone et al., 1995; Sahni et al., 1999; Su et al., 1997). 
In mutant chondroblasts where FGF receptor is constitutively activated shows antiproliferative 
behavior. This is achieved by persistent Stat1 activation which inturn induces the activation of 
p21WAF1, a cyclin-dependent (Cdk) inhibitor (Sahni et al., 1999; Su et al., 1997).These results 
supports that Stat1 is an antiproliferative and pro-apoptotic agent and also explains in vivo why the 
lack of this molecule leads to increased tumor formation. The identification of low levels of Stat1 
in nucleus of unstimulated cells might suggests that Stat1 in cooperation with other transcription 
factors regulate apoptosis by basal expression of responsible genes.
It has been shown that Stat1 is a tumor suppressor (Kaplan et al., 1998) contrastingly when 
Stat1-/- genotype is coupled with tumor suppressor gene p53, there was increase in tumor formation 
spontaneously (Kaplan et al., 1998). In response to IFNγ number of human tumors have no effect 
in terms of Stat1 activation and also growth is retarded in culture (Chin et al., 1997; Kumar et al., 
1997). It was reported that tumor surveillance system which is important in preventing tumors is 
dependent on Stat1 mediated by IFNγ. But the tumor suppression mechanism is not completely 
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understood but, are in part due to lack of immune mediated surveillance and Stat1 in tumor tissues 
(Kaplan et al., 1998; Ouchi et al., 2000).
 Several viruses target Stat or Jak proteins for degradation or inhibit their activation in an 
indirect way (Polyak et al., 2001b; Polyak et al., 2001a). Further Stat1 overcomes the inhibition 
of nuclear translocation of proteins due to vesicular stomatitis virus, by the induction of nuclear 
pore protein Nup98 (Enninga et al., 2002; Her et al., 1997; von Kobbe et al., 2000). These above 
findings shows the importance of Stat or in particular Stat1 mediated signals for resistance to 
infection.
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2. AIM OF THE CURRENT RESEARCH
VSMC migration and later proliferation might be governed by several other cell types by 
interacting with them. Of special importance in this concern are monocytes that infiltrate into the 
site of injury and promote an inflammatory response with the generation of chemotactic mediators, 
culminating in the accumulation of intimal VSMC. Our recent findings demonstrate that the uPA/
uPAR system is upregulated upon VSMC-monocyte interaction in a coculture model and serves 
for the increase in VSMC motility.  Moreover, VSMC growth in coculture is arrested, although 
the underlying molecular antiproliferative mechanism remains unclear.  These findings imply that 
the upregulated uPA production by monocytes following vascular injury acts most likely as an 
endogenous activator of VSMC contributing to the remodeling of vessel wall. A wide array of 
findings supports the idea that components of fibrinolytic system play a significant role in vascular 
diseases, including arterial neointima formation after injury. However, little is presently known 
about how the uPA/uPAR system controls these processes to induce regulated vascular wound 
healing. uPA is an unusual molecule of a dual function, which switches from the proteolytic 
enzyme to signal transducing molecule depending on the environmental challenges. There is an 
increasing body of evidence for the nonproteolytic role for the uPA/uPAR system in vitro and 
in vivo.  These observations suggest that the uPA/uPAR-dependent cellular behavior does not 
reflect modulation of pericellular proteolysis but rather changes in cellular signaling. One major 
signaling cascade activated by uPA in human VSMC in vitro is the Jak/Stat pathway.  The Janus 
kinase Tyk2 is associated with uPAR and serves via the downstream phosphatydilinositol-3-kinase 
(PI3-K)-dependent cascade for the uPA-directed cell migration. Signal transducer and activator 
of transcription Stat1 is strongly activated in response to uPA in VSMC, although the functional 
purpose of this activation remains unclear. Cell culture and animal experiments, as well as clinical 
observations on human cancer cells, suppose that Stat1 is important for growth restraint and can 
be considered the mediator of antiproliferative effects.
The main purpose of this study was to elucidate molecular mechanisms of antiproliferative 
effect observed in VSMC cocultured with monocytes. The results provide for the first time the 
evidence that the uPA expressed by monocytes elicits antiproliferative effect in VSMC achieved 
by activation of Stat1. Activation of Stat1 is induced by the interaction of monocyte-expressed uPA 
with its receptor (uPAR) on VSMC. This might also throw light on the migration of VSMC during 
early stages of remodeling process after vascular injury.
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3. MATERIAL & METHODS
3.1 Chemicals and biochemical substances
 All used chemicals and solutions were of analytical grade and were purchased from Sigma-
Aldrich (Deisenhofen, Germany), Merck (Darmstadt, Germany), Serva (Heidelberg, Germany) 
and Roth (Karlsruhe, Germany). All solutions were maintained at the appropriate pH and filter-
sterilised where ever necessary. 
 MACS Large Cell separation columns, anti-CD11b antibody conjugated with magnetic 
material and the separator were purchased from Miltenyi Biotec GMBH (Bergisch Gladbach, 
Germany). The CELLocate coverslips (square size 175 µm), Microloaders (finely pulled 10 
µl pipette tips) and sterile Femtotips for the purpose of microinjection were purchased from 
Eppendorf AG (Hamburg, Germany).
3.2 Antibodies
3.2.1 Primary antibodies
 The monoclonal anti-Stat1 (C-terminus) and polyclonal rabbit anti-Stat1(N-terminus) 
antibodies were purchased from Transduction Laboratories (Lexington, Kentucky). Polyclonal 
anti-uPAR (R3 clone) antibody was purchased from Monozyme (Kopenhagen, Denmark) and 
monoclonal anti-uPA antibody was purchased from American Diagnostica, Inc. (Greenwich, 
CT). Monoclonal anti-Stat1 (p84/p91) as gel supershift reagent was purchased from Santa Cruz 
Biotechnology Inc. (SantaCruz, CA). Anti-Stat1 pSer727 specific and anti-Stat1 pTyr701 polyclonal 
antibodies were purchased from BioSource International Inc.( Camarillo, California). Monoclonal 
anti-BrdU antibody was purchased from Becton Dickenson (San Jose, CA).
3.2.2 Secondary antibodies
 Secondary, Alexa fluor® 546 conjugated, goat anti-mouse and anti-rabbit IgG (H+L) were 
purchased from Molecular Probes Inc.(Eugene, OR). Peroxidase (HRPO)-conjugated anti-mouse 
Immunoglobins were from Santa Cruz Biotechnology Inc.(sc-2005, Santa Cruz, CA), Sigma 
Chemicals Co (#A9917, St. Louis, MO) or Pierce (# 31430. Rockford, IL).
3.3 Cell culture
3.3.1 Human vascular smooth muscle cells (VSMC)
Human coronary artery VSMC were obtained from Clonetics (San Diego, CA). The cells 
were grown in SmGM2 medium (Clonetics) supplemented with 5% fetal bovine serum and were 
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used between passages 3 and 7. For coculture and cell treatment experiments with nocodazole (5 
µg/ml), uPA and uPAR antibodies the cells were cultured for 24 h in serum-free SmGM2 medium 
and were then treated accordingly.
3.3.2 Isolation of monocytes from whole blood
Monocytes were separated from freshly obtained blood from healthy donors using Biocoll 
(Biochrom KG Seromed, Berlin, Germany) density gradient centrifugation method according to 
the manufacturerʼs instruction. Briefly, blood was collected in 50 ml syringe with sodium citrate 
solution (10 ml of sodium citrate for 40 ml of blood) as anti-coagulant. While drawing the blood 
into the syringe with the anti-coagulant, the syringe was gently rotated so as to mix the blood with 
sodium citrate. The collected blood was diluted 1:2, with sterile PBS pH 7.4. The PBS diluted 
blood was over laid on 12-13 ml of Biocoll solution taken in fresh 50 ml falcon tubes with atmost 
care. Then the tubes with Biocoll and overlaid diluted blood was centrifuged at 3000 rpm for 30 
min at 15 - 20 °C. The leucocytes forms a white ring or boundary between the plasma and Biocoll 
layer,while erythrocytes and granulocytes formed the sediment. The plasma layer was removed 
and the leucocytes were carefully pipetted out with pasteur pipette into a fresh 50 ml falcon tube. 
The cell suspension was washed 2 times (first at 1600 rpm and second at 14000 rpm for 20 min 
each at 20 °C) in sterile PBS so as to remove traces of Biocoll solution. Finally the cell pellet was 
resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum, Penicillin (100 
IU/ml) and Streptomycin (100 µg/ml) for 2-3 h at 37 °C in incubator with 5% CO
2
. After the 
incubation time the medium was removed and the cells were washed gently with sterile PBS so 
as to remove dead cells. Adhered monocytes were detached with trypsin solution and stimulated 
with LPS (100 ng/ml) for 2-3 min and pelleted down by centrifugation. A small aliquot of cell 
suspension was taken before centrifugation and counted using cell counting chamber (Neubauer 
chamber). The cell pellet was resuspended in SmGM2 medium without supplements and then used 
for further coculture with VSMC.
3.3.3 Coculture
VSMC were seeded on sterile coverslips or culture dishes and cultured till they have 
reached appropriate density according to the experimental requirements, in SmGM2 medium 
with supplements. The cells were serum starved for 12-24 h in medium without supplements. 
Then the freshly prepared, LPS stimulated monocytes, resuspended in SmGM2 medium without 
supplements, were directly added on to the dish containing VSMC, at a concentration of 1.9 x 105 
cells per cm2 area and cocultured for a period of 24-27 h at 37 °C in 5% CO
2
 incubator. 
In all the experiments involving coculture, monoculture of VSMC are included as control.
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3.3.4 Preparation of VSMC from u-PA and u-PAR knockout mouse respectively
VSMC were isolated from the aorta of u-PA and u-PAR knock-out mouse respectively, 
(kindly provided by Prof. Peter Carmeliet and Dr. Mieke Dewerchin, Center for Transgene 
Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology; University 
of Leuven, Leuven, Belgium) according to the protocol followed by P. Fallier-Becker et al., with 
certain changes. Briefly, after the excision of the aorta from the mouse, the vessel was made free 
of the fatty tissues surrounding it and cut longitudinally, above said procedure is carried out under 
preparation medium (Hank´s/PBS (1:3) solution). Now the intimal layer consisting of endothelium 
and few intimal smooth muscle cells normally present in the intima was gently scraped with a 
scalpel. Then the vessel surface was washed with the PBS and fresh preparation medium was 
poured on to the vessel. Then the vessel was subjected to two steps of enzyme (collagenase + 
elastase) disaggregation. In the first step, the medial layer was separated from the adventitial 
layer by incubating the vessel for 8-10 min at 37 °C in the enzyme solution-I, with 1.4 mg/ml of 
collagenase and 0.5 mg/ml of elastase and in the second step, the media tissue pieces were digested 
by incubating for 60-90 min in the enzyme solution-II, with 2 mg/ml of collagenase and 0.5 mg/
ml  of elastase to obtain single VSMC. After complete disaggregation an aliquot of the enzyme 
suspension was taken to determine the cell number. Then the cell suspension was centrifuged to 
remove the enzyme. Finally, the pellet was resuspended in culture medium (SmGM2 medium from 
Clonetics supplemented with 5% fetal bovine serum) and seeded in culture dish. After the primary 
cells were confluent, it was passaged at 1:2 till the second passage as the cell growth was slow 
initially and further passaged at 1:6, and used for the experiments passages from 3 – 7.
3.4 Immunofluorescence microscopy
3.4.1 Fixation and permeabilization 
The method followed was according to the protocol given in Haller et al (1995, 1996). 
Whether the cells from coculture or monoculture,the VSMC were treated similarly. The cells on 
the coverslips were washed once with PBS after the said coculture incubation time and fixed in 
4% (w/v) paraformaldehyde in PBS for 15 min at RT, followed by washing twice in PBS. Then the 
cells were permeabilised to analyse the cytoplasmic and nuclear proteins, by incubating the cells 
in icecold 80% (v/v) methanol at –20 °C for 20 min followed by 2 washes in PBS. Finally the cells 
were blocked overnight at 4 °C with 1% (w/v) BSA in PBS.
 For double staining the paraformaldehyde fixed cells were permeabilised with 0.5% Triton 
X-100 (v/v) in PBS and proceeded for blocking with BSA/PBS.
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3.4.2 Immunostaining 
 Paraformaldehyde fixed, permeabilised and overnight 1% (w/v) BSA/PBS blocked cells 
were washed thrice with PBS then further incubated in primary antibody solution. The antibody 
solutions were prepared in 0.2% (w/v) BSA in PBS and centrifuged to remove any precipitates.
 The primary antibody solution was prepared at 10-20 µg/ml concentration and for staining 
the cells on the coverslips 30-40 µl of the antibody solution was added on to each coverslip 
and incubated for 2 h at RT in humidified chambers followed by three washes with PBS. The 
primary antibodies on the cell were detected by counter reacting them with a secondary antibody 
conjugated with fluorescent materials (Alexa 546-,Cy3- or Cy5-) at a concentration of 10 µg/ml 
at RT in humidified dark chambers for 1h. For double staining the cells were incubated in primary 
antibody and corresponding secondary antibody as described above followed by three washes with 
PBS and mounted on to a glass-slide in Mowiol with 2.5% DABCO or Vectashield. The results 
were documented using fluorescence microscope.
 In the case of double staining, particularly staining for the cytoskeleton and 
nucleocytoplasmic proteins the fixed, permeabilised and 1% (w/v) BSA/PBS blocked cells were 
stained initially for cytoskeleton with Alexa 488 phalloidin in 1% (w/v) BSA/PBS and then 
immunostained for nuclear and cytoplasmic proteins.
3.5 Separation of VSMC after coculturing with monocytes using MACS separating system 
After the appropriate incubation of VSMC with monocytes in direct coculture as described 
earlier, medium was removed and the cocultured cells were washed once with the PBS. Cells 
were detached with 5 mM EDTA and centriuged to remove the EDTA. Before centrifugation an 
aliquot of cell suspension was taken to estimate the number of cells in cell counting or Neubauer 
chamber. The cell pellet was resuspended in buffer (PBS supplemented with 2mM EDTA and 
0.5% (w/v) BSA) at 80 µl per 107 cells. The cell suspension was treated with anti-CD11b antibody 
conjugated with the magnetic material at 20 µl per 107 cells and incubated at 6-12 °C for 15-20 
min with repeated gentle shaking. The cells were washed once with 10x-20x the volume of the 
cell suspension with the buffer to remove free and nonspecifically bound antibodies. The washed 
cells were gently resuspended avoiding any clumps in the buffer at 500 µl per 108 cells. In the 
mean time the Large Cell column was placed in the separator with the appropriate holder provided 
and activated by washing with 500 µl of the buffer. Then the cell suspension with free cells and 
cells coupled with antibody complex was applied to the column. While loading care was taken, 
that no air bubble was introduced into the column. The flowthrough was collected in fresh tube 
which contains VSMC whereas the monocytes complexed with the magnetic material conjugated 
CD11b IgG, are trapped in the column which was in a strong magnetic field. A small aliquot of 
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the flowthrough was observed under the microscope to check the purity of the cells. If the cell 
suspension was not pure and retained some amount of monocytes, the above procedure was 
repeated to get pure VSMC suspension. Pelleted down cells from the flowthrough were further 
processed to prepare the lysate. 
 
3.6 Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from VSMC that were either monocultured or cocultured 
with freshly isolated monocytes from human blood. Cells were detached by treating with 5 mM 
EDTA, cocultured VSMC were separated from monocytes using MAC cell separating system as 
described earlier. After centrifugation, the cell pellet was resuspended in buffer A (10 mM HEPES, 
pH 7.9, 1.5 mM MgCl
2
, 10 mM KCl, 0.5 mM DTT), containing the protease inhibitors (1mM 
PMSF, 5mM Iodoacetamide, 0.1 mM Quercitin, 10 μg/ml Aprotinin, 10 μg/ml Leupeptin and  300 
μM Sodium Vanadate ) and incubated on ice for 15 min. After homogenization in a Wheaton 0.1-
ml homogenizer, the nuclei were collected by centrifugation. The pellet was resuspended in buffer 
B (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM MgCl
2
, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM 
DTT), containing protease inhibitors, and incubated on ice for 30 min, followed by centrifugation 
at 13,000 g (5 min, 4 °C). The supernatant was dialyzed against buffer C (20 mM HEPES, 20% 
glycerol, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT), containing protease inhibitors for 2 h at 4 
°C, followed by centrifugation by 13,000 g for 5 min at 4 °C. The supernatant proteins were used 
immediately or aliquoted and stored at –80 °C. For lysates from cells stimulated with Interferon γ, 
the cells were stimulated for 30-45 min, before detachment with EDTA.
Binding reaction was performed for 30 min on ice in a volume of 20 µl, containing 4 µg of 
nuclear protein extracts, 40 ng of poly(dI-dC), 4 µl of 5x binding buffer (1x binding buffer: 20 
mM HEPES, pH 7.9, 50 mM KCl, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 10% glycerol) with 
or without 20-50 fold excess of cold competitor or of unrelated competitor, and a 32P-labeled probe 
(3 x 104 cpm). In supershift EMSA, protein extracts were incubated with 2 µg of experimental or 
isotypic control antibody, prior to the addition of 32P-labeled probe. DNA-protein complexes were 
separated on 5% polyacrylamide gel in Tris/glycine buffer at 4 0C
The following double-stranded oligonucleotides were purchased from Santa Cruz 
Biotechnology, Inc. and used in this study: 
GAS/ISRE, 5´-AAGTACTTTCAGTTTCATATTACTCTA-3´, 27 bp 
AP-1,  5´-CGCTTGATGACTCAGCCGGAA-3´, 21 bp 
5´-End-labeled probes were prepared with [γ-32P] ATP using T4 polynucleotide kinase and 
were gel-purified on NAP-5 Sephadex G-25 DNA-grade columns. The reaction mixture contained 
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milli Q water, 10x kinase buffer, 1-50 pmol of oligonucleotide (GAS/ISRE), 40 µCi of [γ-32P] ATP 
and 10 IU/µl of T4 polynucleotidekinase and the reaction volume was set at 20 µl. The reaction 
was stopped after incubating for 30-60 min at 37 °C with constant mixing with 2.5 µl of 0.5 M 
EDTA. Then the above mixture was applied on to a NAP-5 Sephadex G-25 DNA grade column, 
which was washed, in advance with TNE buffer (100 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 
mM EDTA) and kept ready for loading. Wash the column once with 600 µl of TNE buffer and 
elute with TNE buffer by collecting the eluant 100 µl per tube. Normally the fraction 9 shows 
highest cpm, when an small aliquot is counted using scintillation counter, which is used for the 
experiments.
3.7 Sodium dodecyl suphate-polyacrylamide gel electrophoresis (SDS-PAGE)
For separation of protein of interest from complex mixtures standard Laemmli (1970), 
discontinuous, one-dimensional SDS-PAGE was used. Minigel format (9.0 cm x 5.5 cm) was 
employed for the above purpose and electrophoresis apparatus was from Bio-Rad Laboratories 
(Modell Mini-Protean II with power supplier Modell 1000/500, Munich, Germany). The gel was 
run at constant power supply at 30 mA per gel and voltage set to 200 mV, till the bromophenol 
blue front reached the bottom.
3.8 Western blot analysis
3.8.1 Semi-dry blotting 
The electrotransfer of proteins from a polyacrylamide gel on to PVDF-membrane is carried 
out in semi-dry condition using an semi-dry blotting apparatus from Bio-Rad Laboratories (Modell 
Trans-Blot SD with power supplier Modell 1000/500) at 110 mA and 20 mV for 50 min per one 
transfer sandwich.
3.8.2 Immunodetection of the transferred protein on PVDF membrane 
 After the complete transfer of the protein from the gel onto the PVDF membrane the 
membrane was incubated for 1 h at RT in PBS-T with 1% BSA in order to block the nonspecific 
free binding sites. The membrane was incubated in primary antibody solution in PBS-T with 1% 
(w/v) BSA for 2 h at RT or overnight at 4 °C. After the membrane is washed thrice, for 10 min 
each with PBS-T with 1% (w/v) BSA, it was incubated in HRPO conjugated secondary antibody 
in PBS-T with 1% (w/v) BSA for 1 h at RT. The membrane was washed thrice, 10 min each with, 
PBS-T. Specifically bound antigens are visualised by incubating the membrabne in peroxidase 
substrate Luminol (Western Lightning Chemiluminiscence Reagent, PerkinElmer Life Sciences, 
Inc., Boston, MA). Protein bands appear within few minutes, the output is emitted as blue light 
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due to the oxidised luminol substrate which was recorded as black images on a X-ray film (CL-
xposure™ Film, Pierce, Rockford, IL).
3.9 Enzyme linked immunosorbent assay (ELISA)
Human Interferon-γ, uPA and uPAR were detected from cell culture supernatants using 
commercially available ELISA kits (human Interferon-γ  from R&D Systems, Inc., Minneapolis, 
MN; human uPA from American Diagnostica, Inc. Greenwich, CT and uPAR  from Monozyme, 
Hoersholm, Denmark), according to the manufacturer´s instructions. Briefly, the assay employs 
the quantitative sandwich enzyme immunoassay technique, cell coculture supernatants from 
day-1 till day-4 were collected and PMSF was added to avoid any protein degradation followed 
by centrifugation to remove any particulate matters. The supernatants were concentrated using 
Centricon Centrifugal Filter Units (Millipore, Bedford, Massachusetts) cut-off molecular weight 
at 10,000 kDa.
3.9.1 For human Interferon-γ  and human uPA  
 The standards and samples were pipetted 100 µl each, into the wells of the microplate 
which is precoated with polyclonal antibody, specific for target protein and any target protein 
present is bound to the immobilized antibody. After the incubation time of 2 h at RT, each well 
was aspirated and any unbound substances were washed away with washing buffer (solution of 
buffered surfactants with preservatives) followed by addition of target protein specific enzyme-
linked polyclonal antibody to the wells. Following a wash to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells and incubated for 30 min at RT. Color 
develops in proportion to the amount of target protein bound in the initial step and it was stopped 
by addition of stop solution (2 N sulphuric acid) in the case of IFN-γ ELISA The optical density of 
each well was measured at 450 nm using a microplate reader (MWG-Biotech GmbH, Ebersberg, 
Germany) with the wavelength correction set at 540 nm or 570 nm. In the case of ELISA for uPA, 
phosphatase reaction was continuously monitored with the plate in the reader and the reading was 
recorded at intervals of 10 min. The absorbance was read at 405 nm.
3.9.2 For uPAR  
 Immunoplates MaxiSorp (NUNC, Roskilde, Denmark) wells were coated with antibody 
by incubating overnight with coating antibody solution provided in the kit at 4 °C. After thorough 
washing with washing buffer (0.1% (w/v) Tween 20 in PBS) the remaining protein binding sites 
were blocked with 2% BSA in washing buffer followed by washing. Then provided standard and 
biological samples were diluted with dilution buffer (1% (w/v) BSA (Sigma, A-7906) in washing 
Materials & Methods
34
buffer) appropriately and were pipetted 100 µl per well in triplicates and dilution buffer as control 
and incubated for 1h at 20 °C. After washing with washing buffer, detecting antibody solution, 
was added at 100 µl, to each well and incubated for 1h at 20 °C followed by washing. Specific 
antibody-antigen-detecting antibody complex, is then conjugated by an enzyme for the purpose of 
detection by incubating with phosphatase-conjugate solution for 1h at 20 °C. After washing with 
washing buffer followed by distilled water, fresh substrate solution (prepared immediately before 
use by dissolving one p-NPP tablet in 12 ml substrate buffer) was added, 100 µl to each well and 
incubated for 90 min at 20 °C. The phosphatase reaction was continuously monitored with the 
plate in the reader and the reading was recorded at intervals of 10 min with the absorbance read at 
405 nm.
3.10 Microinjection 
VSMC were cultured on CELLocate coverslips till the cell density was around 60-65%. 
Serum starved cells for 12-14 h, were microinjected with anti-Stat1 pSer727 antibody using Nikon 
DIAPHOT-300 inverted microscope and micromanipulator type MO-8 with hydraulic joystick 
(Narishige, Tokyo). The Femtotip was attached to microinjector PL-188 (Nikon, melville, New 
York) preset to constant outflow pressure 0.1-0.4 psi (1 psi=6.89 kPa). The concentration of 
microinjected antibody was 25 µg/ml in PBS with Mg2+ and the antibody solution was centrifuged 
for 10 min at 13000 rpm at RT to remove precipitates and then loaded into the Femtotip using 
microloader. The medium was supplemented with penicillin and streptomycin to avoid any 
infection due to the exposure of cells to the outside environment. Approximately the injection 
time was around 10-20 min. Microinjected cells were washed twice with fresh medium with the 
antibiotics and fresh medium is added. After incubation of cells at 37 °C in 5% CO
2
 incubator for 2 
h, they are cocultured with freshly prepared monocytes as described earlier. Further the cocultured 
cells were used for proliferation assay. As control nonspecific IgG was microinjected and treated 
accordingly.
3.11 Single cell proliferation assay
Apart from the above microinjected cells, for proliferation assay cells were plated on coverslips 
and cultured to a density of 60-65%, the cells were serum starved for 24 h and cocultured with 
freshly prepared monocytes. A set of controls were included, as follows, monoculture of VSMC 
without supplements, with 5% FCS and coculture with 5% FCS. After the incubation time the 
cells were treated with BrdU (Sigma, final, 100 µM) and further incubated for 8-10 h at 37 0C. We 
washed the cells with PBS and fixed in 4% paraformaldehyde. Further washed thrice in PBS and 
permeabilised with 0.5% Triton X-100 in PBS at RT and blocked with 1% BSA in PBS overnight 
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at 4 0C. Further the cells were incubated with a cocktail containing anti-BrdU monoclonal antibody 
(Becton Dickinson), 1% BSA, 2x DNAse buffer solution and DNAse solution (to digest DNA) for 
1 h at RT. Following washing cells were incubated with Alexa 546- labeled goat anti-mouse IgG 
(Molecular Probes) for 1 h at room temperature. After washing, DNA was counter-stained with 
Hoechst 33258, followed by washing with PBS and mounted in Mowiol with 2.5% (w/v) DABCO 
and documented the results with flourescence microscope.
3.12 Cell treatments
As described under cell culture VSMC were cultured on coverslips or in culture dishes 
according to the experimental requirements till the density was around 60-70% for preparation of 
cell lysates and 30-45% confluent for immunocytochemial studies. The cells were serum starved 
for 12-24 h and treated with nocodazole (5 µg/ml) in medium without supplements and after 90 
min of incubation at 37 °C in 5% CO
2
 incubator, freshly prepared monocytes were added to initiate 
the coculture. Whereas in the case of cell treatment with monoclonal anti-uPA (25 µg/ml) and 
polyclonal anti-uPAR (R3 clone) (100 ng/ml) antibodies and nonspecific IgG (25 µg/ml) serum 
starved VSMC were incubated in the respective antibody solutions 1 h prior to the addition of 
monocytes.
 In all the above treatments monoculture of VSMC were included as control and treated 
appropriately.
3.13 General protein chemistry techniques
3.13.1 Protein estimation by Bradford assay / Coomassie dye binding assay
 The protein estimation was done by Bradford´s method (1976). The assay was carried out 
in microtiterplates (Macrowell Plate, Nunc, Roskilde, Denmark). The calibration standard used 
was BSA (4-40 µg/ml) and the volume of the standards and the samples used per well was 50 µl 
in triplicates. After the addition of sample and standards, 200 µl of the Bradford´s reagent (Protein 
Assay Dye Concentrate, Bio-Rad Laboratories, Munich, Germany) diluted at 1:5 in water was 
added. The absorbance was measured at 595 nm with a Microtiterplate-Photometer from Molecular 
Devices (Modell ThermoMax, Sunnyvale, CA) using a SOFTmax PRO P1.12 Software.
3.13.2 Dialysis
 The Dialysis of the Protein samples were done in Spectra/Por® Dialysis molecular porous 
membrane tubing (Spectrum®, Gardena, CA). The membrane used had MWCO of 12-14 kDa. 
The dialysis was carried out in dialysis buffer 100 fold more than the sample, at 4 °C with constant 
stirring.
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4. RESULTS
4.1 VSMC stop proliferating when cocultured with monocytes
As proliferation is an important functional aspect of cells in tissue remodeling and wound 
healing it sounded wise to check the proliferative status of VSMC in our coculture model 
which to a certain extent mimics the in vivo environment in vessel injury. For this purpose, we 
implemented single cell proliferation assay, where the cells were pulsed with BrdUrd for 8-12 
h. After the incubation period, the cells were fixed in paraformaldehyde and further subjected 
to immunofluorescent-staining. In addition to stain for BrdUrd, the DNA was counterstained 
with Hoechst. VSMC showed antiproliferative behavior when they were cocultured with freshly 
isolated monocytes from human blood, even if the cells were cultured in the presence of 5% FCS 
when compared to the control (Figure 7). These findings are supported by the earlier findings of 
Proudfoot et al., 1999, where they have reported that monocytes does not stimulate smooth muscle 
cell growth. It has been reported by numerous authors that uPA/uPAR system is involved in tissue 
remodeling and wound healing by affecting cell adhesion, migration and proliferation. 
Based on the above obtained results and findings, our line of investigation followed two 
assumptions. First, we supposed that VSMC growth inhibition might be mediated by transcription 
factor Stat1, which is a known powerful antiproliferative molecule (Bromberg, 2001). 
Figure 7. Inhibition of VSMC proliferation in coculture.
VSMC were cocultured with LPS-treated monocytes and treated with BrdU to analyze DNA synthesis. Incorporation 
of BrdU was detected by immunofluorescence using monoclonal antibody against BrdU (lower panel). DNA was 
counter-stained, with Hoechst 33258 (upper panel). The above stainings were performed in both serum-treated and 
nontreated samples and VSMC in monoculture was the control.
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  Second, that the required activation of Stat1 in VSMC might be provided by the 
monocyte-expressed uPA. This idea was based on our previous studies demonstrated that Stat1 is 
activated in VSMC in response to exogenous uPA (Dumler et al., 1999a; Dumler et al., 1998) and 
that the uPA expression in monocytes cocultured with VSMC is strongly upregulated (Kusch et al., 
2002). 
4.2 Stat1 is upregulated in VSMC cocultured with monocytes
STAT proteins as the name itself indicates are signal transducers in the cytoplasm and 
activators of transcription in the nucleus. Upon ligand binding to the receptors on the cell 
surface the Stat proteins get phosphorylated through JAK kinases (Jak1 or Tyk
2
). Once the Stat 
proteins are phosphorylated they form homodimers or heterodimers and gets translocated to the 
nucleus to activate transcription of genes by binding to the DNA. In order to investigate whether 
Stat1 in VSMC is affected via the coculture with activated monocytes, we initially performed 
immunocytochemical studies to visualize the intracellular distribution of Stat1 (Figure 8a). We 
cocultured VSMC with freshly prepared monocytes from human blood which were activated with 
LPS before the initiation of coculture. After the incubation period of 24-27h the cells were washed, 
fixed and stained. Surprisingly, immunofluorescent staining with anti-Stat1 monoclonal antibody 
revealed that nucleus showed a strong staining for Stat1 protein in coculture. This shows that Stat1 
protein was activated after 24-27 h of coculture and translocated to the nucleus leading to a striking 
accumulation  (right panel). In contrast, no Stat1 nuclear translocation occurred when monocytes 
were absent (left panel).
As activation of Stat1 requires the phosphorylation of tyrosine at around 700 residue 
(Schindler et al., 1992) and phosphorylation of STAT1 on S727 greatly augments its transcriptional 
potency (Horvath, 2000; OʼShea, 1997; Stark et al., 1998), we assessed the phosphorylation site 
of Stat1, activated in coculture. Nuclear and cytosolic fractions were prepared from VSMC 
cocultured with and then separated from monocytes using MACS separating system. The 
subcellular fractions were monitored for serine and tyrosine phosphorylation status of Stat1 
by Western blotting using phosphospecific polyclonal antibodies (Figure 8b). The antibodies 
specifically recognized Stat1 phosphorylation on Ser727 and Tyr701. VSMC in monoculture served 
as controls. Serine phosphorylation of Stat1 in cocultured VSMC was promptly elevated (upper 
panel), whereas activation of Stat1 tyrosine phosphorylation, although reliable, was several folds 
less and could be observed only after longer exposure time than those used for Stat1-pSer727 
phosphorylation (middle panel). Although Stat1 phosphorylation on Ser727 was increased both in 
cytosolic and nuclear fractions, the total amount of Stat1 protein in these fractions (lower panel) 
clearly demonstrates that activated Stat1 was mainly translocated to the nucleus. Whole cell lysates 
from both the VSMC stimulated with IFNγ and unstimulated were included as positive controls. 
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Figure 8. Stat1 in VSMC is activated in coculture. 
a, Stat1 immunofluorescence in VSMC in coculture with monocytes and monoculture control.
b, VSMC after coculture were separated by MACS separating system  and analyzed for pSer727Stat1 and pTyr701Stat1 
in whole cell lysate, cytosolic (C) and nuclear (N) fractions by subjecting to SDS-PAGE and Western blotting with 
anti- pSer727Stat1 and anti- pTyr701Stat1 rabbit polyclonal antibodies respectively. As a control for Stat1 amount, blots 
were analyzed for Stat1 using anti-Stat1 monoclonal antibody (lower panel). 
The purity of the subcellular fractions was checked by using anti-α-actin antibody.
Further, to distinguish between the Stat1 activation and expression in our experimental model 
we analysed the mRNA profiles. The results of RT-PCR analysis confirms that there is no change 
in Stat1 expression on day1 in coculture when compared to the control VSMC monoculture, on 
day2 though there was increase but not significant and inhibition on day3 of coculture (Figure 9). 
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These above findings demonstrate that monocytes play a pivotal role in the activation of Stat1 and 
its nulear translocation but not expression.
As far as only activated Stat proteins can bind to the DNA after translocation to the nucleus, 
a DNA binding assay or EMSA (electrophoretic mobility shift assay) was next addressed, as an 
Figure 9. Stat1 expression in VSMC monocultured and cocultured with monocytes. 
VSMC monocultured and cocultured with monocytes were analysed for Stat1 at mRNA level by RT-PCR using TaqMan 
analysis and the results graphically represnted.
appropriate tool to check for Stat activation. This assay analyses the mobility of the activated 
Stat proteins, which get specifically bound to the oligonucleotides. Further to support our above 
findings, the activation of Stat1 in VSMC when cocultured with monocytes was examined at 
the DNA-binding level. Nuclear extracts and a 32P-labeled GAS/ISRE oligonecleotide probe 
containing a consensus binding site specific for Stat1 were used to analyse the nuclear extracts 
(Figure 10). With coculture, the DNA-protein complex was increased, compared to monoculture 
controls. In gel supershift assay, with anti-Stat1 specific antibody, the intensity of the DNA binding 
was reduced as this specific antibody identified Stat1 and inhibited the formation of prominent 
DNA-protein complex. This mobility shift and supershift assay clearly determined that Stat1 in 
VSMC was translocated and bound specifically to the GAS/ISRE DNAʼ s sequence upon activation 
in the presence of monocytes.
Appropriate localization of proteins is crucial for their physiological function and regulation. 
Once the cells are stimulated, proteins are the main vehicles, which transmit incoming signals. The 
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Figure 10. Binding of Stat1 to GAS/ISRE elements. 
GAS/ISRE binding activity of nuclear extracts prepared from VSMC that were cocultured with monocytes and also 
from monoculture were analyzed by EMSA.  Open arrow indicates the position of protein-32P-GAS/ISRE complex and 
solid arrow indicates position of free probe. 
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transmission of the signal is accomplished by interaction with other molecules with or without 
movement into another location in the cell to the target organelle where the final response is 
seen. Activation of transcription factors can occur in the cytoplasm or at the cell membrane. Once 
activated, they translocate to the nucleus through nuclear pores (Kaffman and OʼShea, 1999). 
However, little is known about the mechanisms of transport to the nuclear pores. Transport through 
the cytoplasm could, a priori, be active along microtubules as observed for p53 (Giannakakou et 
al., 2000), or passive, by diffusion, as in a random walk. To determine whether the translocation 
of Stat1 to the nucleus is dependent on the integrity of the cell or whether this translocation 
requires the elements of the cytoskeleton as channels, VSMC were treated with the inhibitor of the 
structural element. The inhibitor nocodazole, which disrupts the formation of microtubules, was 
used to determine the influence of these structural elements on Stat1 translocation. VSMC were 
pre-incubated in the absence or presence of the drug for 90 min, before the addition of freshly 
prepared monocytes and the coculture setting was incubated under continued drug treatment for 
24-27 h. The efficacy of the drugs was confirmed by changes in cell morphology. Further, we 
performed immunofluorescent studies, probing the cells with anti-Stat1 antibody and Alexa 546 
conjugated secondary antibody. We found that translocation of Stat1 was not affected though the 
cytoskeleton was disrupted and comparable to the control (Figure 11). This is in agreement with 
the earlier finding that nuclear translocation of Stat1 in response to IFNs is not dependent on an 
intact cytoskeleton (Lillemeier et al., 2001).
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Figure 11. Stat1 translocation is not dependent on an intact cytoskeleton. 
α-Actin immunofluorescence in VSMC treated and untreated with nocodazole (upper panel) and Stat1 
immunofluorescence in VSMC treated with nocodazole prior to coculture with monocytes and monoculture (lower 
panel). 
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4.3 VSMC Stat1 activation in coculture requires uPA/uPAR and is interferon-γ-resistant
Activation of Stat1 resulting in dimerization and finally translocation to nucleus in VSMC 
requires an external stimulus and we supposed that monocytes are a potent inducer of this Stat1 
activation in VSMC. Moreover, our recent findings showed that uPA is a known potent activator of 
Stat1 in VSMC (Dumler et al., 1998), and that uPA expression by monocytes and uPAR expression 
on VSMC are both upregulated in coculture (Kusch et al., 2002). Based on these above results, 
it was hypothesized whether this might explain the observed activation of Stat1. To analyse this, 
inhibiting the interaction of uPA with its specific receptor uPAR in the coculture system sounded 
promising. VSMC were treated separately with monoclonal anti-uPA and polyclonal anti-uPAR 
specific antibodies. In separate experiments VSMC were treated with respective antibodies 1h 
prior to the addition of monocytes and medium was not changed before the addition of monocytes 
so that the antibody treatment was continued during the incubation time. After the incubation 
time of 24-27 h the cells were washed, fixed and stained. The immunofluorescent staining with 
monoclonal anti-Stat1 antibody revealed the localization of Stat1 in VSMC (Figure 12). This 
treatment abrogated Stat1 nuclear translocation occurred in the coculture system.
Figure 12. Stat1 activation in VSMC depends on uPA/uPAR signaling. 
VSMC were treated with anti-uPA and anti-uPAR antibodies separately, before coculture with monocytes, and were 
analysed for Stat1 by immunofluorescence. Total cell number and the number of cells with translocated Stat1 were 
counted for each view field. 9-10 view fields have been evaluated in each experiment. The result is a representative of 
3 experiments.
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Figure 13. Inhibition of  Stat1 binding to GAS/ISRE  elements. 
VSMC were treated with anti-uPA antibody before the addition of monocytes; VSMC in monoculture is control. GAS/
ISRE binding activity of nuclear extracts prepared from the above anti-uPA antibody-treated VSMC was analysed by 
EMSA. 
Consistent with these data, the EMSA showed Stat1 activation was blocked in coculture 
when VSMC were treated with anti-uPA antibody (Figure 13). VSMC were treated with anti-uPA 
antibody prior to the addition of monocytes. After the said incubation time, nuclear extract was 
prepared from VSMC separated from monocytes by MACS separating system as explained in the 
methods. In all the above experiments monoculture of VSMC with and without treatments were 
used as controls.
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Figure 14. Stat1 activation in VSMC depends on uPA/uPAR signaling. 
Immunofluorescent staining for Stat1 in mouse VSMC in coculture with monocytes from uPA-/- and in VSMC from 
uPAR-/- mice cocultured with wild-type monocytes using anti-Stat1 rabbit polyclonal antibody. As a control, wild-type 
cells and VSMC from uPA-/- are included.
 To rule-out any flaw and to verify additionally these findings, uPA- and uPAR-deficient 
mice were used. The monocytes from uPA-/- mice and VSMC from uPAR-/- mice were isolated 
accordingly as explained in the methods section and used for coculture setting. Figure 14 shows 
Stat1 cellular distribution in wild-type VSMC cocultured with the uPA-deficient monocytes 
(middle panel) and in the uPAR-deficient VSMC cocultured with wild-type monocytes (right 
panel). As expected, in both the cases, as one of the candidate in the uPA/uPAR system was 
absent. The required signal for the tyrosine/serine phosphorylation of Stat1 was not conveyed as 
the ligand-receptor binding was hindered. As a result, in both cases Stat1 was mainly localized 
in cytoplasm and in the perinuclear space, whereas its nuclear translocation was minimal.  In 
contrast, we observed again pronounced Stat1 nuclear translocation when wild-type VSMC and 
wild-type monocytes were used in the coculture system (left panel). This indicates that uPA/
uPAR interaction plays a pivotal role in activation of latent cytoplasmic Stat1, dimerization upon 
activation and nuclear translocation where it accumulates and drives transcription.
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Figure. 15. VSMC do not respond to IFN-γ stimulation in coculture.
Lysates were prepared from MACS separated VSMC, upon coculture and stimulated with IFN-γ.  Proteins were 
separated on SDS-PAGE and analyzed by Western blotting with anti-pSer727Stat1 rabbit polyclonal antibody.  VSMC 
in monoculture with and without stimulation are included.  As a control for gel loading, anti-Stat1 antibody was 
used.
Since interferon-γ (IFN-γ) is a strong activator of Stat1 (Ihle, 2001; Platanias and Fish, 1999), 
we used IFN-γ as a positive control. Surprisingly, IFN-γ had no or less effect on Stat1 activation 
when VSMC were cocultured with monocytes. After the stipulated period of 24-27 h of coculture 
the medium was changed for fresh medium containing IFN-γ and incubated for 30 min. After 
the said incubation time VSMC were separated from monocytes using MACS separation system. 
VSMC were lysed and the prepared cell lysate was subjected to Western-blot analysis using anti-
Stat1 antibody. Western-blot analysis of proteins from cocultured VSMC stimulated with IFN-γ 
shows only slight increase in Stat1 phosphorylation, as compared to Stat1 phosphorylation profile 
in the IFN-γ-stimulated monocultured cells (Figure 15).
Further, it was interesting to check the DNA binding behavior of the Stat1 in IFN-γ stimulated 
VSMC in coculture. Nuclear extracts was prepared from the IFN-γ stimulated VSMC in coculture 
and Stat1-DNA binding was monitired by EMSA. Consistent with the data on Western blotting, 
IFN-γ did not produce any significant increase in the intensity of Stat1-DNA binding in cocultured 
VSMC (Figure 16). Monoculture of VSMC was used as a control and it was treated appropriately 
as coculture.
One possible explanation for the observed decreased sensitivity to IFN-γ might be the 
desensitization of VSMC induced by probable overexpression of IFN-γ in coculture since human 
leukocytes are capable of synthesizing interferon (Farrar and Schreiber, 1993). To confirm in our 
hands, we measured the IFN-γ in the supernatants from the coculture system. 
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Figure 16. Binding of Stat1 to GAS/ISRE elements does not increase with IFN-γ stimulation .
DNA binding activity of nuclear extracts prepared from VSMC treated with or without IFN-γ, from both monoculture 
and coculture were analysed by EMSA. The presence of stat1 in the observed complex was tested by using anti-Stat1 
antibody.
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Figure 17. Upregulation of IFN-γ secretion in coculture.
ELISA quantification of IFN-γ in the monoculture (monocytes) and coculture supernatants performed using the 
commercially available kit. Monocytes from 4 different donors were cocultured with VSMC and the cell culture 
supernatants were quantified for IFN-γ. The value of the monoculture on day1 was considered to be one and 
accordingly fold of increase was calculated both in monoculture and coculture for different days in each donor. The 
mean of the values from different donors is shown in the graph (± SD, n=4).
For the purpose of studying the kinetics of IFN-γ secreted in the coculture system, it was 
incubated for 4 days. Cell culture supernatants were collected from the coculture from day1-day4. 
To rule out whether the specificity of IFN-γ secretion depends on an individual, monocytes isolated 
from freshly obtained blood from 4 donors were cocultured separately with VSMC accounting to 
4 samples. Cell culture supernatants from monoculture of VSMC and monocytes were included 
as control. Quantitative ELISA was employed to measure the IFN-γ level using ELISA kit and 
eventually found a two-fold increase of IFN-γ in our coculture compared to monoculture (Figure 
17). The kinetics of this increase reached maximum on day-4 of coculture.
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4.4 Stat1 elicits the antiproliferative effect that requires monocyte-expressed uPA and 
VSMC-expressed uPAR
In the cell cycle progression S phase represents the period in which cellular DNA make its 
own copy by means of replication.  As far as Stat1 is a strong antiproliferative agent, it seems that 
Stat1 activation and translocation to the nucleus inhibits the replication of DNA or posseses a stop 
signal for growth of the cell. This activation of Stat1 is achieved by the interaction of uPA with 
its specific receptor uPAR as supported by our above results. To prove the hypothesis that locally 
produced uPA by activated monocytes binds to the VSMC cell-surface uPAR and induces Stat1 
activation that mediates antiproliferative effect, we relied again on monocytes from uPA-/- and 
VSMC from uPAR-/- mice. Combination of both cell types was used for coculture, the first by using 
VSMC from wild type and monocytes from uPA-/- mice. Second, by using VSMC from uPAR-/- 
and monocytes from wild type mice and third with both cell types from wild type mice as control. 
Further after the incubation period of coculture, the cells were subjected to proliferation assay 
using incorporation of 5-bromo-2´-deoxyuridine (BrdUrd). This nucleoside gets incorporated 
into the cellular DNA in the place of thymidine. The BrdUrd pulsed cells were stained by using 
antibody against BrdUrd, which positively stains cells that are actively synthesizing DNA during 
this period. In addition, the DNA was counterstained with Hoechst stain to count the number of 
cells. The results were documented as described in the methods. With wild-type cells, VSMC in 
monoculture showed proliferation that was substantially increased when the FCS concentration 
was raised to 5%.  This proliferation was sharply attenuated to low levels in the co-culture system, 
regardless of the FCS concentration (Figure 18a).  With uPA-/- monocytes, coculture increased 
proliferation in the absence of FCS and had no effect on proliferation in 5% FCS (Figure 18b). 
With uPAR-/- VSMC, coculture again caused no proliferation inhibition and the results looked 
identical to those with uPA-/- monocytes (Figure 18c, compared to Figure 18b). To completely 
exclude the autocrine loop of Stat1 activation a combination of VSMC from uPA-/- and wild-type 
monocytes were used. In agreement with the other data we observed inhibition of VSMC growth 
and comparable to the results obtained with wild-type VSMC (Figure 18d, compared to Figure 
18a) 
To get the evidence that VSMC growth inhibition was mediated by the upregulated Stat1, 
several experimental approaches were used. Firstly, to show the importance of any given protein, 
one important and appropriate tool used widely is inhibiting the expression of the said protein 
by transgenic mode or by knocking out the gene responsible for its expression. So we used the 
Stat1 knock-out mice. VSMC from Stat1-deficient mice were isolated as described in the methods 
and used these cells for coculture with wild-type monocytes followed by proliferation assay, as 
described above.  
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Figure 18. Inhibition of VSMC proliferation in coculture requires uPA/uPAR signaling.
VSMC upon coculture with monocytes were treated with BrdU.  Incorporation was detected by immunofluorescence 
using monoclonal antibody against BrdU. Cells were counted using Hoechst 33258 nuclear staining.  Representives 
of n experiments are shown.  a, Result (n=4) using wild-type VSMC and wild-type monocytes.  b, uPA-/- monocytes and 
wild-type VSMC were used for coculture (n=3).  c, uPAR-/- VSMC and wild-type monocytes were used (n=3). d, uPA-/- 
VSMC and wild-type monocytes were used for coculture (n=3).The coverslips were counted in one given field for the 
number of cells in blue filter for Hoechst 33258 and for number of proliferating cells in red filter for BrdU (Alexa 546). 
Cells were counted (mean ± S.D. of 5-7 fields).
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Figure 19.  Stat1 mediates antiproliferative effect in VSMC in coculture. 
VSMC from Stat1-/- and monocytes from wild-type mice were used for coculture and proliferation assay, as indicated 
in the legend to Fig. 18.
Monocultured Stat1-/- VSMC showed even in the absence of FCS a higher proliferation level, 
as compared to wild-type cells, and this proliferation was not further inhibited upon coculture 
(Figure 19).
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Further, to support the above findings one, more widely used tool to study the importance 
of a particular protein is to block at the RNA level. In this direction RNA silencing technology 
for the stable and specific inhibition of Stat1 expression in human VSMC using retroviral RNA 
interference vector (Cottrell and Doering, 2003) was used.  Figure 20 shows that Stat1 expression 
in these cells (Stat1si-VSMC) was abrogated, as verified by TaqMan RT-PCR (left panel).  In 
proliferation assay, Stat1si-VSMC behaved similar to Stat1-/- VSMC. They displayed increased 
proliferation level in monoculture that was not affected by coculture with monocytes (right panel, 
shown for –FCS coculture).
Figure 20.  Downregulation of Stat1 expression restores VSMC proliferation. 
Stat1si-VSMC with downregulated expression of Stat1 (left panel) were used for coculture setting and proliferation 
assay (right panel).
The above observation was supported by microinjection experiments. As in microinjection 
one can target a particular protein without disturbing other molecules and tracing the effect of that 
particular protein of interest, antibody against Stat1 Ser727 phosphorylation site was injected to the 
cytoplasm. Upon injecting the antibody, Stat1 was neutralized in VSMC, blocking particularly 
Stat1 at Ser727 phosphorylation site. These microinjected VSMC were washed and incubated with 
fresh medium for 1-2 h and further used these cells for coculture setting followed by proliferation 
assay. As a control VSMC injected with non-specific IgG was treated accordingly as the sample. 
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Figure 21.  Inhibition of Stat1 phosphorylation restored VSMC proliferation. 
VSMC were microinjected with pSer727Stat1 antibody and then cocultured. 100-120 cells were microinjected in each 
experiment and the result shown is a representative of 4 experiments. As a control, non-microinjected and non-specific 
IgG injected VSMC were included. Microinjected and control cells were used for proliferation assay (top panel), and 
for immunocytochemistry (bottom panel).
The active antibody completely blocked the antiproliferative effect (Figure 21, top panel). 
Consistent with these data, no Stat1 nuclear translocation was observed in VSMC microinjected 
with specific antibody, whereas microinjection of control antibody did not affect Stat1 nuclear 
accumulation (Figure 21, bottom panel).
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5. DISCUSSION
Arteriosclerosis, the pathological common base of acute and chronic coronary diseases, 
remains the leading cause of morbidity and mortality. Percutaneous vascular interventions have 
become successful and widely used treatments for patients with the atherothrombotic diseases. 
However, chronic restenosis remains one of the major limitations of these procedures leading to 
the obstruction of dilated arteries (Ellis et al., 1998; Forrester et al., 1991).  The major reasons for 
restenosis development are local changes in medial vascular smooth muscle cell proliferation and 
migration, followed by increased synthesis of extracellular matrix activated in response to injury 
during revascularisation.  Over several months, these processes result into neointima expansion 
and plaque formation, finally leading to luminal narrowing (Gallo et al., 1998).  Thus, future 
progress in the prevention of restenosis mainly depends on the development of the therapeutic 
approaches selectively influencing VSMC activation at the site of vascular intervention. 
  We show that the interaction of human VSMC with peripheral-blood-derived monocytes in 
a coculture model results in the inhibition of VSMC growth. The mechanism involves activation 
of the transcription factor Stat1 in VSMC. This activation is mediated by uPA expressed on the 
monocytes, which signals the uPAR on the VSMC. The observations imply that monocytes regulate 
VSMC responses through components of the fibrinolytic system and provide an important link 
between the uPA/uPAR signaling machinery and VSMC function. The findings may be relevant 
to VSMC behavior in the face of vascular injury. 
The response-to-injury hypothesis proposes that increased endothelial permeability or frank 
disruption features leukocyte infiltration. By unknown mechanisms, VSMC then migrate from 
the media into the intima. Here, they proliferate and synthesize an extracellular matrix to form an 
intimal lesion that may impede flow (Libby et al., 1991; Clowes et al., 1991; Reidy et al., 1992). 
Several in vivo and in vitro studies suggest that VSMC migration precedes proliferation and that 
the uPA/uPAR signaling system may be involved (Clowes et al., 1990; Carmeliet et al., 1997; 
Okada et al., 1998). There is also indirect evidence from humans that inhibition of these early 
processes can lead to long-term inhibition of the cellular changes (Topol et al., 1994). We asked 
whether VSMC migration is associated with feedback inhibition of cell proliferation and whether 
this balance might be controlled by cross-talk of the underlying signaling pathways. We used a 
coculture model in which human VSMC were directly cocultured with human peripheral-blood-
derived monocytes. Although such alternative in vitro models have obvious limitations, they may 
be helpful for studying communication between 2 or more cell types neighbored in the arterial 
vessel wall. 
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Moreover, most data on cell regulation by uPA come from experiments on cultured cells 
exposed to exogenous purified or recombinant uPA or its peptides, sometimes at fairly high 
concentrations, making interpretations uncertain. A more specialized in vitro experimental system 
allowed us to overcome this problem. It is generally considered that the uPA/uPAR system controls 
the VSMC´s functional behavior mainly via the induction of intracellular signaling. Since uPAR 
is glycosylphosphatidylinositol (GPI)-anchored and devoid of transmembrane and cytoplasmic 
domains, it is thought to associate with the transmembrane adaptors of yet incompletely known 
nature, interacting with uPA and/or uPAR and mediating the uPA-induced intracellular signaling 
which culminate in cell migration and proliferation (Irigoyen et al., 1999; Rabbani et al., 1992; 
Wei et al., 1996). The existence of the tandem of transmembrane signaling and GPI-anchored 
receptors was recently shown for some neurotrophic factors, such as GDNF, neurturin and CNTF 
(Treanor et al., 1996; Trupp et al., 1995). In the case of uPAR, such a function might be attributed 
to integrins, G protein-coupled receptors, adaptor protein gp130, which have been demonstrated to 
interact directly with uPAR with the functional consequences for the cell adhesiveness, migration 
and signaling (Wei et al., 1996).
The large body of data provide evidence that uPA-induced cell migration and proliferation 
are supplemented with the rapid and transient activation of intracellular serine and tyrosine 
phosphorylation (Bohuslav et al., 1995; Busso et al., 1994; Dumler et al., 1993), with activation of 
Src kinases (Konakova et al., 1998; Resnati et al., 1996), focal adhesion kinase (FAK) and mitogen 
activated protein kinase (MAPK) (Nguyen et al., 1999; Nguyen et al., 1998; Tang et al., 1998). 
However, in spite of the availability of such detailed information about uPA-related signaling 
events, it is not clear how adhesive, migratory, and mitogenic signals eliminating from the uPAR 
are differentiated. Moreover, numerous studies on uPA-directed signaling cascades in different 
cell types have figured out that the identified signaling pathways are exclusively cell specific.
In human VSMC, the Jak-Stat pathway is the predominant signaling cascade triggered 
by uPA/uPAR. It has been demonstrated in our previous studies that uPA activates and uPAR is 
associated with two Janus kinases, namely Jak1 and Tyk2 (Dumler et al., 1998; Dumler et al., 
1998a ). Moreover, activation of Stat1, Stat2 and Stat4 in response to physiological concentrations 
of uPA was additionally shown, although the functional consequences of this activation remained 
unexplored (Dumler et al., 1999a).
In the present study we have made an attempt to fill up the gaps in the molecular mechanisms 
involving uPA/uPAR system and Jak-Stat pathway in vascular remodeling using the direct 
coculture system, where we used VSMC and monocytes both of human origin. This model 
mimicks to certain extent the in vivo environment of an injured vessel wall, where the monocytes 
can directly interact with the medial VSMC upon the loss of endothelial integrity. Such alternative 
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in vitro models might be very helpful to overcome the obvious limitations of animal models and 
to study communication between two or more cell types, which are neighbored in the arterial 
vessel wall. Using this coculture system, we targeted some of important molecules in the signaling 
cascade involving uPA/uPAR at the cell surface and Stat1 as a critical candidate downstream of 
the cascade within the cell.
We demonstrate here that VSMC in the presence of activated monocytes show an 
upregulation or activation of Stat1 and its nuclear translocation.  By disrupting the microtubule 
formation using nocodazole, we demonstrated the lack of dependence of Stat1 translocation to the 
cytoskeleton. The activation of Stat1 is accomplished by the interaction of uPA with its specific 
receptor. The source of uPA is none other than the monocytes, as our previous studies indicate that 
expression of uPA was increased in monocytes in coculture with VSMC, whereas the expression 
of uPAR on VSMC was increased (Kusch et al., 2002). Our finding suggests that monocytes play a 
decisive role in activation of uPAR-directed signaling in VSMC involving Stat1 as the downstream 
effector molecule that elicits the antiproliferative effect in VSMC contributing to the pathogenesis 
of vascular disease.
As it is known from several studies, Stat1 is a strong antiproliferative agent. We have 
demonstrated the uPA/uPAR-related antiproliferative effect of Stat1 in VSMC by providing 
several lines of evidence. Thus, blocking uPA and uPAR by antibodies and using VSMC and 
monocytes from the uPAR- and uPA-deficient mice, we show that uPA/uPAR system plays a 
pivotal role in activating Stat1 by phosphorylation at ser727, translocation to the nucleus and DNA 
binding. Further, we demonstrate a functional importance behind this Stat1 activation i.e, growth 
inhibition. This growth inhibition is evident from the proliferation assay using the cells from the 
uPA and uPAR knock-out mice and additionally by blocking the Stat1 ser727 phosphorylation site 
using specific antibody in microinjection experiments. In addition it is confirmed that Stat1 is the 
candidate responsible for this growth inhibition by the experiments with Stat1 knock mouse and by 
silencing the Stat1 by using Stat1 retroviral construct (Stat1si) where the cells proliferated without 
any inhibition.
IFN-γ plays a pivotal role in defense mechanisms by switching on the signaling cascade 
involving Stat proteins and Janus kinases. It seems likely that in different cellular contexts, more 
than one kinase pathway can converge on Stat1 (Chow et al., 2001). IFN-γ was an unreliable 
Stat1 activator in our coculture system, although clear-cut Stat1 activation was observed under the 
monoculture condition. One possible explanation for the observed decreased sensitivity to IFN-γ 
might be the desensitization of VSMCs induced by the overexpression of IFN-γ in coculture given 
that leukocytes are capable of synthesizing interferon.  ELISA reports in the present study showed 
Discussion
57
two-fold increase in the IFN-γ secretion in the coculture model. At the same time, the Western 
analysis showed inhibition of IFN-γ-dependent Stat1 stimulation in VSMC or no effect of IFN-γ 
on the coculture system. This peculiar behavior can be explained as, in the present case the IFN-γ 
stimulation may be inhibited where the uPA signaling was dominant and this might have masked 
the effect of IFN-γ on coculture system. Alternaively, IFN-γ inactivation by limited proteolysis 
cannot be excluded (Duval-Jobe et al., 1995). Although more work is needed to explore the 
possibility in greater detail, these data suggest that IFN-γ might use the Stat1-independent pathway 
in the physiologic situation in which Stat1 activation by uPA is predominant. 
Taken together, we suggest a new role for the non-proteolytic function of the fibrinolytic 
system in the propagation of vascular remodeling following injury through the interplay of VSMC 
with monocytes (Figure 22).  Besides the Jak/Stat pathway, other mediators might contribute to 
Figure 22. 
Schematic representation of the uPA/uPAR-directed Stat1 signaling in coculture.
The study proposes uPA/uPAR signaling at the cell surface results in phosphorylation of Tyk2 and/or Jak1 recruiting 
Stat1 to activate, dimerize and translocate to the nucleus, leading to gene expression, inhibiting cell proliferation and 
via a different mechanism promote cell migration involving PI3-K and small GTPases.
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VSMC growth inhibition by uPA.  Future studies will have to determine whether other signaling 
proteins play a role in this model.  Their elucidation will no doubt provide potential new targets for 
the treatment and prevention of restenosis.
 The precise and rapid propagation of this signaling cascade demands strict and flexible 
negative regulatory processes that remain unexplored. The nature of the negative regulators 
involved may have therapeutic implications. Our schematic representation is based on the 
experimental coculture model and corresponds to in-vivo data showing an increase in VSMC 
proliferation in uPA-deficient mice (Carmeliet et al., 1997d)  and the expression of uPA only 
in proliferating VSMC in the injured rat carotid artery (Clowes et al., 1990). Why VSMCs 
use the paracrine and not the autocrine loop for uPA-directed intracellular signaling and how 
this cell-cell cross-talk remains tightly regulated temporally and spatially in live cells in the 
face of vascular injury remain unresolved. Many factors other than uPA are involved in the 
development of vascular disease. However, we have identified a mechanism that suggests how 
the uPA/uPAR signaling system may contribute to this process through cell-cell communication. 
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